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Abstract 
Glucocorticoids (GCs) are steroid hormones widely prescribed to treat inflammatory disorders 
and are regarded as anti-inflammatory molecules. GCs classically induce the expression of anti-
inflammatory genes, while repressing pro-inflammatory genes via its endogenous cell 
receptor; the glucocorticoid receptor (GR). Emerging evidence, however, suggests that the 
mechanisms of GR action are more complex than previously assumed, with many reports of 
pro-inflammatory actions of GCs via the GR. While chronic exposure to GCs has been noted as 
anti-inflammatory, reports suggest that acute exposure can increase peripheral immune 
responses. Specifically, the GCs have been shown to positively regulate the innate immune 
response, which may be important in preventing the local, affected area from being 
immunocompromised. Furthermore, the GR can crosstalk with cell signalling pathways 
involved in pro-inflammatory responses, such as the TNFα pathway, to reciprocally modulate 
the expression of pro-inflammatory genes. The mechanisms behind the GR’s pro-inflammatory 
actions and crosstalk with inflammatory inducers are not well understood.  
GC’s pro-inflammatory actions are attributed to GC insensitivity in asthma patients. The 
insensitivity is attributed to long-term GC usage, and the increase in Th17 neutrophilic airway 
infiltration. A proposed hypothesis for the increase in neutrophils in the airways was that it was 
due to an increase in expression of chemokines by epithelial cells due to GC exposure. The pro-
inflammatory, chemoattractant cytokine C-C motif chemokine ligand 20 (CCL20) has been 
previously shown to be induced by GCs and pro-inflammatory inducers in human bronchial 
cells, with positive modulation of their responses occurring with co-stimulation.  
The present study investigated whether the GC dexamethasone (dex) and the pro-
inflammatory inducer TNFα could induce CCL20 expression in a variety of human epithelial cell 
lines, and a simian fibroblast cell line. Using Real-Time Quantitative Reverse Transcription PCR 
(qRT-PCR), it was confirmed that dex can induce CCL20 mRNA expression, and modulate the 
TNFα-induced expression in some, but not all cell lines. Moreover, in the HeLa cell line, there 
was an apparent synergistic response between dex and TNFα, and modulation of the CCL20 
response was observed between dex and the pro-inflammatory inducers phorbol 12-myristate 
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13-acetate (PMA), interferon γ (IFNγ) and lipopolysaccharide (LPS). The GR was shown to be
required for the GC induction and modulation of CCL20 mRNA expression. Using promoter-
reporter assays, the results showed that the NFκB binding site was necessary for the activation 
by the pro-inflammatory inducers, but not dex, while the STAT binding region was necessary 
for the IFNγ activation. Interestingly, lack of the STAT binding site on the promoter-reporter 
construct caused IFNγ to have repressive effects on CCL20 activation. Stimulation of cells by 
the pro-inflammatory inducers in the presence or absence of dex had no effect on the total 
levels of the p65 subunit of NFκB, while dex did appear to cause GR turnover as expected. The 
results show that dex, via the GR, is able to crosstalk with different pro-inflammatory inducers 
to induce and potentiate CCL20 mRNA expression and promoter activation. The mechanisms 
of CCL20 induction and crosstalk with the GR may be different for each pro-inflammatory 
inducer, however.  
Regulation of CCL20 expression is complex, with many transcription factors converging on the 
promoter region to modulate its expression. This thesis shows that the NFκB binding site is 
important for the overall induction level of the promoter, however it is not necessary for the 
dex induced activation. The potentiation of the dex response by pro-inflammatory inducers 
may be due to the GR interacting with the AP-1 and C/EBP transcription factors, which have 
been shown to positively interact to increase gene expression. The potentiation of the dex 
response does not require the activation of NFκB, as IFNγ does not activate the transcription 
factor, yet can potentiate the dex response. 
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Inflammation is a biological response to harmful stimuli such as trauma, pathogen detection 
or irritants (Feghali et al., 1997). Inflammation is a protective process, involving immune cells, 
blood vessels and inflammatory molecular mediators such as cytokines. Inflammation can be 
categorized into two phases, the acute and chronic phase (Feghali et al., 1997). The acute 
phase is a rapid response, characterized by an increase in blood flow and membrane 
permeability, an increase in leukocyte trafficking and release of inflammatory mediators. The 
chronic phase is a long term inflammatory response, characterized by the development of a 
humoral response, mediated by B-cells, and involving the release of specific antibodies. The 
chronic phase also involves the activation of macrophages, natural killer cells and T-cells (Abbas 
et al., 2009). In both acute and chronic inflammation, a host of inflammatory molecules are 
released such as cytokines, with some cytokines contributing to both phases of the immune 
response.  
Cytokines which play a key role in mediating acute inflammation include IL-1β, TNFα, IL-6, IL-
11, GCSF, GM-CSF and chemokines such as IL-8, CCL19 and CCL20. Cytokines important in 
mediating the chronic phase can be subdivided into two categories; those involved in cellular 
inflammation, and those in humoral inflammation. Examples of those in cellular inflammation 
are IL-2, IL-12, interferons (IFNs) such as IFNγ and TNF-α and –β. Those involved in humoral 
inflammation include IL-4, IL-10, IL-13, and transforming growth factor-β (TGF-β) (Feghali et 
al., 1997; J.-M. Zhang et al., 2007). 
There is a functional difference in CD4+ T-cell responses involved in chronic inflammation 
based on their profile of cytokine secretion, namely Type 1 T helper (Th1) and Type 2 helper 
(Th2) cells. Th1 cells provide protection against intracellular bacteria, protozoa, fungi, and 
several viruses and produce IFNγ, TNFβ, IL-12 and 1L-2 which activate macrophages and 
cytotoxic T-cells. Th2 cells provide protection against multicellular parasites, extracellular 
bacteria, some viruses, soluble toxins, and allergens, and produce IL-4, IL-5, IL-10, and IL-13, 




the humoral immune response (Belardelli et al., 2002; Romagnani, 1999). The actions of Th1 
and Th2 cells inhibit each other, with IL-12, TNFβ and IFNγ inhibiting Th2 cells, and IL-4, IL-10 
and IL-13 inhibiting Th1 cells (Mosmann et al., 1996). Cytokines can also be classed as pro-
inflammatory, such as IL-6 and TNFα, and anti-inflammatory, such as IL-10 and IL-4 (Elenkov et 
al., 2002). The secretion of the two different classes of cytokines is important for fine-tuning 
and regulating the inflammatory response. The most potent antagonizers of both acute and 
chronic inflammation, however, are glucocorticoids (Barnes, 1998).   
 
  




The inflammatory response is critically important for protection against pathogens and their 
antigens. Cells at the site of an infection not only need to elicit an inflammatory response to 
protect against further cell and tissue damage, but also elicit the correct response for the 
particular pathogen (Medzhitov, 2008). For example, a response to a virus may require cell 
apoptosis, and the recruitment of NK cells, while a bacterial infection may require phagocytosis 
by macrophages. However, in both cases the acute and chronic immune response may be 
necessary. The ability of the local area to elicit the correct immune response relies on the 
detection of the cause of inflammation (Takeuchi et al., 2010). Pattern recognition receptors 
(PRRs) such as toll-like receptors (TLRs), play an important role in eliciting the appropriate 
immune response.  
Lipopolysaccharide (LPS) is a component of the outer membrane of Gram-negative bacteria 
and is a potent activator of the immune response (Schletter et al., 1995). LPS is recognized by 
Toll-like receptor 4 (TLR4), a membrane-spanning protein, and co-receptor with CD14, a 
glycosylphosphatidylinositol-linked cell surface glycoprotein necessary for sensitive responses 
to LPS (Ulevitch et al., 1995). Activation of TLR4 leads to a signalling cascade which activates 
NFκB and causes the expression of mediators of inflammation such as IL-1β, IL-6, IL-8 and TNFα 








IFNγ is the only member of the type II class of interferons and exists as a 17kDa dimer. IFNγ is 
important for maintaining chronic inflammation, and is produced by NK cells, CD4+ Th1 cells 
and CD8+ cytotoxic T cells (Schoenborn et al., 2007). IFNγ binds to its heterodimeric membrane 
cell receptor consisting of Interferon gamma receptor 1 (IFNGR1) and Interferon gamma 
receptor 2 (IFNGR2), which activates the JAK-STAT pathway (Aguet et al., 1988; Schoenborn et 
al., 2007). IFNγ is critical for immunity against viral and intracellular bacterial infections, and is 
involved in tumour control, while also being able to promote adhesion and binding required 
for leukocyte migration onto epithelial cells (Filipe-Santos et al., 2006; Ikeda et al., 2002; Romer 
et al., 1995). IFNγ is the primary cytokine that defines Th1 cells, with IFNγ secretion causing 
the maturation of undifferentiated CD4+ cells (Th0 cells) to differentiate into Th1 cells, while 
also supressing Th2 cells (Mosmann et al., 1996; J. Zhu et al., 2008). It has been shown that 
IFNγ does not act via the NFκB transcription factor (Andreakos et al., 2004; Cheshire et al., 





Tumour necrosis factor α (TNFα) is a cytokine involved in the acute immune response and is 
part of the tumour necrosis factor superfamily, whose other member is lymphotoxin-alpha, 
formerly known as tumour necrosis factor-beta (TNFβ). TNFα is mainly produced by 
macrophages but is also produced by many other cell types such as CD4+ lymphocytes, NK cells 
and neutrophils (Beutler et al., 1988). TNFα is a 17kDa protein and exists as a homotrimer 
(Smith et al., 1987). The cell receptors for TNFα are the membrane-bound TNF receptor type 
1 (TNFR1), which is expressed in most cells, and TNF receptor type 2 (TNFR2), which is typically 
expressed in immune cells (Ashkenazi et al., 1998). TNFα can cause apoptotic cell death, induce 
fever, inflammation and inhibit tumorigenesis, while also inducing the production of IL-6 in 




thereby creating a cascade of cytokines with overlapping properties, enhancing the acute 
inflammatory response (Feghali et al., 1997). NFκB and AP-1 are both activated by TNFα 





Phorbol 12-myristate 13-acetate (PMA) is a diester of phorbol, and a potent activator of the 
signal transduction enzyme protein kinase C (PKC) and its ability to activate PKC is due to its 
structural similarities to an endogenous PKC activator, diacylglycerol (Blumberg, 1988; 
Castagna et al., 1982). As an activator of PKC, which is a mitogen-activated protein kinases 
(MAPK), PMA therefore acts as an inflammatory inducing signal (Robinson, 1992). PMA has 
been shown to copurify with PKC, and inhibition of PKC prevents the inflammatory actions of 
PMA (Niedel et al., 1983; Tahara et al., 2009). PKC plays an important role in many signalling 





Glucocorticoids (GCs), such as cortisol which is the endogenous GC in humans, are the most 
commonly used drugs in the treatment of inflammation (Barnes, 1998). Glucocorticoids are 
used to treat inflammation caused by the detection of antigens or pathogens, tissue injury due 
to various types of trauma, asthma, and various auto-immune diseases such as rheumatoid 
arthritis (Feghali et al., 1997). Glucocorticoid-mediated effects are generally due to the 
suppression of inflammatory cytokines, such as IL-6 and TNFα, and the induction of anti-
inflammatory cytokines, such as IL-10 (Ashwell et al., 2000). Glucocorticoids have also been 
shown to have negative side-effects, especially in their long-term use, such as their induction 
of inflammatory chemokines, cytokines and innate immune-related genes. This has been 
hypothesised to be involved in the negative effects of glucocorticoids (Galon et al., 2002; 




(HPA) axis with the GR playing a vital role in the immune system, homeostasis and metabolism 
(Del Rey et al., 2008). 
 
 
1.2.1 Receptor structure and domains 
 
The glucocorticoid receptor (GR), also known as nuclear receptor subfamily 3, group C, 
member 1 (NR3C1) is the receptor to which GCs bind (Oakley et al., 2013). The GR is a steroid 
receptor and therefore shares many structural similarities with other steroid receptors such as 
the progesterone receptor, the androgen receptor and mineralocorticoid receptor (Cato et al., 
2002). Through alternate splicing there exists 4 isoforms of the GR; GRα GRβ, GRγ, GR-A and 
GR-P, with GRα being the classical receptor subtype, and being the most extensively studied 
(Oakley et al., 2011). For the purposes of this study, all subsequent mentions of GR will be 
referring to GRα. The glucocorticoid receptor consists of 777 amino acid residues with a weight 
of 95 kDa (Hollenberg et al., 1985). The receptor can be divided into three functional domains 
namely the N-terminal domain (NTD), the DNA-binding domain (DBD) and the ligand-binding 
domain (LBD), with a hinge region between the DBD and LBD (Fig 1.1) (Griekspoor et al., 2007). 
To date, no complete crystal structure of the GR has been solved, and this may be due to the 
unordered structure of the NTD of the receptor (Lu et al., 2006). Other regions of the GR, 
however, have been resolved via X-ray crystallography, such as the LBD (Bledsoe et al., 2002). 
The NTD has the highest level of variation between the different GR species and is directly 
involved in the mechanisms of GR transcription. The NTD is a site for protein-protein 
interactions with other transcription factors, such as TATA box-binding protein (TBP), cAMP 
response element binding protein (CREB)-binding protein (CBP) and steroid receptor co-
activator 1 (SRC-1) (Kumar et al., 2005). The region within the NTD that allows for these 
interactions is the transcriptional activation region 1 (AF1), which can constitutively act in the 
absence of the LBD and is also required for maximal transcriptional activity (Kumar et al., 2001). 
This site is important for GR modulation and crosstalk with other pathways as it is a site for 
post-translational modifications, such as phosphorylation (Faus et al., 2006). The DBD is the 
most conserved region between different GR isoforms and is responsible for direct DNA 




Jun (Yang-Yen et al., 1990). Connected to the DBD via the flexible hinge region is the LBD, which 
is responsible for the binding of hormone ligands. The LBD consists of twelve amino acid 
residues, and four β-strands which form the ligand binding pocket of the receptor. The LBD has 
also been shown to be involved in nuclear translocation and homodimerization (Bledsoe et al., 
2002). The LBD also contains the ligand-dependent transactivation domain 2 (AF2), which is 
involved in co-factor recruitment and binding to heat-shock proteins (Bledsoe et al., 2004). 
 
 
Figure 1.1. Amino acid length and different mechanistic regions of the glucocorticoid α receptor. NTD/AF-
1, DBD, hinge region and LBD/AF-1 regions as described in (Griekspoor et al., 2007).  
 
 
1.2.2 Mechanisms of GR action 
 
1.2.2.1 Ligand binding and nuclear translocation 
 
In the absence of ligand, the majority of GR exists within the cytoplasm, although there is 
evidence to suggest unliganded GR shuttling in and out of the nucleus (Ritter et al., 2014). 
While in the cytoplasm, the inactive GR monomer exists in a heteromeric multi-protein 
complex. It is bound with chaperone proteins such as heat-shock protein 90 (HSP90) and 
immunophilins such as FK506 binding protein 51 (FKBP51) (Dalman et al., 1989; Murphy et al., 
2005; Zhou et al., 2005). GCs are able to pass through the cell membrane by passive diffusion 
as they are lipophilic (Lu et al., 2006). Once within the cell, GCs can bind the GR within the LBD, 
causing conformational changes of the receptor, and translocation to the nucleus (Flammer et 
al., 2011). GR dimerization occurs within the cytoplasm before nuclear translocation (Savory 
et al., 2001). Dimerization is classically needed for transactivation, but not necessarily for GR 
transrepression (Malkoski et al., 1999). Two nuclear localization signals (NLs) are exposed 




hinge region of the GR and allow for the GR to enter the nucleus via the nuclear pore (Savory 
et al., 1999). Fig 1.2 depicts the mechanisms of GR action. Mifepristone (RU486), is a potent 
antagonist of GR, and acts via binding to the LBD of the receptor (Bourgeois et al., 1984).  
 
 
Figure 1.2. Mechanisms of GR action. 
Simple, schematic diagram of the postulated GR mechanism of action. Shown is the GR either binding 








1.2.2.2 Transcriptional regulation 
 
Once within the nucleus, the GR can cause its transcriptional effects by either binding directly 
to the DNA, or by tethering to other transcription factors and proteins in a tethering 
mechanism. Classically, direct binding to DNA results in transactivation and an increase in 
transcription, while tethering to other transcription factors leads to transrepression, and a 
decrease in transcription (Schäcke et al., 2004).  
 
 
1.2.2.2.1 Direct DNA binding 
 
The active GR once in the nucleus can bind directly to GREs, which are DNA target sequences, 
and cause transcription of GC-responsive genes. The consensus sequence of the GRE is the 
palindromic 15-bp sequence 5’-GGTACAnnnTGTTCT-3’ (where n represents any nucleotide) 
(Barnes, 1998). Genes may contain one, or many simple-acting GRE sites within their promoter, 
such as the serine/threonine protein kinase (SGK1) promoter with one, while the mouse 
mammary tumour virus (MMTV) promoter contains many half-sites (Beato, 1993; Schoneveld 
et al., 2004). Genes may also contain glucocorticoid response units (GRUs), where transcription 
requires not only GR binding to the GRE, but also the binding of other transcription factors, 
such as activator protein 1 (AP-1) proteins and TBP, to adjacent binding sites (Schoneveld et 
al., 2004). The GR is also able to bind as a monomer to GRE half sites (Luisi et al., 1991).  
These effects classically lead to the transactivation of the particular gene, and therefore an 
increase in transcription. The GR does this by recruiting the basal transcription machinery, 
chromatin remodelling complexes, co-activators, as well as a variety of other transcription 
factors which facilitate GR-mediated transcription (Chinenov et al., 2013). 
 
The GR is also able to transrepress the expression of genes by binding directly to DNA via 
specific, negative glucocorticoid response elements (nGREs) (Malkoski et al., 1999). The nGRE 
is similar to the GRE sequence, but contains more variability in its sequence, 5’-
ATTACnnTnTGATCn-3’. The GR is able to transrepress genes by competing with positive acting 




contains an nGRE which overlaps with the TATA box, thereby preventing the binding of TBP, 






In the classical model of transcriptional regulation, besides direct DNA binding, the GR can also 
bind to other transcription factors, via protein-protein interactions, to modulate genetic 
expression. This tethering to other transcription factors allows the GR to modulate the 
expression of genes that do not contain GREs or nGREs (Ratman et al., 2013). Tethering is 
generally recognised as a mechanism for GR transrepression, as few examples of tethering 
causing transactivation to exist (Arambašić et al., 2010; Johansson-Haque et al., 2008). The 
prevailing mechanism for GR transrepression of pro-inflammatory genes is via GR tethering to 
the transcription factors activator protein 1 (AP-1) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) (Adcock et al., 2006). The precise mechanisms of how the 
GR interacts directly with AP-1 and NFκB is still unclear, although the DBD region of the GR has 
been shown to be vital for these interactions (Kassel et al., 2007).  
 
 
1.2.2.3 Post-translational modifications 
 
The GR is a target for many post-translational modifications, which play an important role in 
modulating the activity of the receptor and also provides an important mechanism for crosstalk 
between cell signalling pathways (Faus et al., 2006). Post-translational modifications affect the 
GR’s transcriptional regulation, protein-protein interactions and degradation, via the 
phosphorylation, ubiquitination, sumoylation and acetylation of specific amino acid residues 
on the receptor (Duma et al., 2006).    
Phosphorylation of the GR plays an important role in GR activity, and also serves as an 




an increase (Kino et al., 2007) and a decrease (Avenant, 2009) in transcriptional activity, 
suggesting regulation in a species- or cell- specific manner (Avenant, 2009; Kino et al., 2007).  
 
 
1.2.3 GR Crosstalk 
 
Cell signalling crosstalk provides for fine-tuned and appropriate cell responses to stimuli. Cell 
signalling crosstalk can occur at many nodes (Campbell et al., 2002). In fact, this is an important 
characteristic of cellular signalling, as it allows for many levels of interaction between signalling 
pathways (Taniguchi et al., 2006). An example where cell signalling crosstalk is important is 
that of the immune response. Fig 1.3 depicts crosstalk between various cell signalling pathways 
with regards to inflammatory ligands, although this diagram is simplified from its true 
complexity. Cells must not only elicit an effective and efficient response to pathogens and 
trauma, but also prevent an overshooting of the response, which may lead to further tissue 
damage (Nathan et al., 2010). Therefore, a high level of communication between signalling 
pathways involved in immune function is vital, with various levels of interaction that can either 
enhance, or repress specific the responses. When cells encounter pathogens, or a foreign 
antigen, an inflammatory response is elicited, resulting in the release or expression of 
cytokines, chemokines, adhesion molecules, receptors and enzymes critical to resolve the 
cause of inflammation (K. Newton et al., 2012). Once the cause of inflammation has been 
appropriately resolved, the immune response needs to be repressed, to prevent detrimental 
effects and chronic inflammation. Glucocorticoids play an important role in the immune 
response, as they classically elicit an anti-inflammatory response, with both natural and 
synthetic glucocorticoids being the most prescribed as anti-inflammatory medication, due to 
their potent immunosuppressive properties. Glucocorticoids are able to induce the expression 
of anti-inflammatory genes such as GILZ and IL10, while also repressing the expression of pro-
inflammatory genes such as IL6 (Waage et al., 1990). Due to its important role in immune 
function, the GR is therefore able to affect, and be affected by other signalling pathways 





This can occur via transcriptional modulation of genes, but also through indirect methods, such 
as post-transcriptional and post-translational effects. This multi-levelled attribute of crosstalk 
allows for many nodes of input from multiple signalling pathways, and therefore a tightly 
regulated and sensitive network in response to many specific signals.  
 
 
Figure 1.3. Abridged, schematic model of cell signalling pathways for the GR and mediators of 
inflammation.  
GC (A), TNFα (B), LPS (C), PMA (D) and IFNγ (E) abridged cell signalling pathways and different promoter 
regions they interact with is shown (Chow et al., 1999; Karsan et al., 2000; Robinson, 1992; Savory et 
al., 1999; Schoenborn et al., 2007; Warren, 1990). The signalling pathways cause transcription factor 














1.2.3.1 GR genomic actions 
 
1.2.3.1.1 Direct modulation 
 
In response to stimuli, the GR is able to cause the transcription of genes important in immune 
regulation. As discussed in Chapter 1.2.2, the GR is classically activated by GC binding, causing 
its translocation to the nucleus, binding to GREs, and the increase of transcription of target 
genes such as GILZ and IL10 (Berrebi et al., 2003). The activated GR is also classically able to 
repress the expression of genes, such as IL6 and IL1β, by tethering to other transcription factors 
(S. W. Lee et al., 1988; Waage et al., 1990). This direct modulation of genes is rapid, as the GR 
already resides in the cell in an inactive state and does not require de novo synthesis (Baschant 
et al., 2010). GCs, instead of suppressing the inflammatory actions of TNFα, have been shown 
to cooperatively regulate TLR2 expression (Hermoso et al., 2004). The NFκB site, STAT-binding 
element, and a 3’ GRE on the TLR2 promoter have been shown to be important for this 
cooperative crosstalk.  
 
 
1.2.3.1.2 Indirect Modulation 
 
The GR can also regulate the expression of genes, which in turn regulate the expression, or 
function, of other proteins. This indirect regulation allows for more nodes of crosstalk, and a 
larger network of regulated immune function genes. The GR is able to shuttle between the 
cytoplasm and nucleus and can affect the expression of genes even when it is unliganded 
(Ritter et al., 2014).  
An example of indirect modulation of the GR is via glucocorticoid-induced leucine zipper (GILZ), 
which is rapidly and ubiquitously induced by GCs. The GILZ protein is able to repress 
transcription of specific genes by interacting with TFs such as NFκB, AP-1 and C/EBPs (Ronchetti 




the expression of genes regulated by TFs such as NFκB, via the inhibitive interaction with GILZ. 
GCs via the GR are therefore able to modulate the expression of genes, and crosstalk with 
other signalling pathways, indirectly.  
The GR is able to indirectly crosstalk with the TLR4 signalling pathway, by increasing the 
sensitivity of myeloid progenitors to LPS. Co-stimulation with GCs and LPS causes an 
overexpression of pro-inflammatory cytokines in these cells when differentiating into 
macrophages (T. Y. Zhang et al., 2007). This result may be dependent on when cells are 
stimulated with GCs and LPS, as stimulation with GCs 1 h following LPS challenge is 
immunosuppressive, while administration of the GCs prior to LPS has been shown to increase 
the immune response and release of cytokines (Frank et al., 2010). 
GCs can indirectly crosstalk with the Janus kinase (JAK)/STAT signalling pathway via suppressors 
of cytokine signalling (SOCS). Interestingly, GCs have been shown to suppress the expression 
of SOCS-3 (Paul et al., 2000). This in turn prevents the suppression of inflammation by SOCS-3 
and has been thought to be a mechanism for GC resistance in asthma patients.  
GCs are able to suppress the LPS-induced expression of cytokines TNFα and IL-6. GCs are able 
to indirectly modulate the activity of MAPKs, such as by increasing the transcription of dual-
specificity phosphatases (DUSPs), which in turn dephosphorylate MAPKs (Tchen et al., 2010). 
The GR can also directly repress TLR4 signalling by interfering with the interferon regulatory 
transcription factor 3 (IRF3)/p65 interaction with Interferon-stimulated response element 
(ISRE) containing genes (S. Ogawa et al., 2005).  
 
 
1.2.3.2 GR Non-genomic actions 
 
GR non-genomic actions are characterized whereby inhibitors of transcription and protein 
synthesis do not affect its actions (Falkenstein et al., 2000). The non-genomic actions of the GR 
are rapid, occurring within minutes, and therefore make it difficult to be explained by genomic 
means (Croxtall et al., 2000). The non-genomic activity of the GR can either occur via cytosolic 
GR, or membrane-bound GR (Bartholome et al., 2004; Wehmeyer et al., 2014).  
The presence of GCs has been shown to modulate the activity of many signalling pathways in 




signalling pathways and are therefore an important target for GC repression of inflammation. 
The three main MAPK subfamilies in mammalian cells are the extracellular signal-regulated 
kinases (ERKs), the p38 MAPK, and the c-Jun NH2-terminal protein kinase (JNK) (Cargnello et 
al., 2011). GCs acting via the GR are also able to rapidly modulate MAPKs through non-genomic 
methods.  
The MAPK p38 is rapidly phosphorylated via the actions of active DUPS1. This suggests a 
possible indirect mechanism for GR/TLR4 signalling pathway crosstalk (Bhattacharyya et al., 
2007). Activation of the GR has been shown to repress the Raf, MAPK/ERK kinase (Mek) 
signalling pathway in a non-genomic manner (Croxtall et al., 2000). Stimulation of rat 
hippocampal cells with cortisol showed rapid activation of JNK and p38, although there are 
cases showing the opposite effects (Qi et al., 2005). The non-genomic crosstalk between the 
GR and MAPKs is also reciprocal, with the MAPKs able to phosphorylate the GR (De Bosscher 
et al., 2003). Activated GR has also been shown to interact with the phosphatidylinositiol 3-
kinase (PI3K)/Protein kinase B (Akt) signalling pathway in a non-genomic, PKC dependant 
manner (Solito et al., 2003). An example of a pathway that utilizes the PI3K/Akt signalling 
cascade is the epidermal growth factor receptor (EGFR). GCs have been shown to increase the 
activity of the EGFR, although it was not shown whether this occurred via non-genomic means 
(Sekiyama et al., 2012). As stated previously, GCs can indirectly interact with the JAK/STAT 
pathway by inhibiting the expression SOCS-3. The GR is also able to directly interact with the 
SOCS-1 protein to crosstalk with the JAK/STAT pathway in a non-genomic manner. Activation 
of SOCS-1 by IFNγ was shown to inhibit GR activity via interaction of the LBD of the GR and the 
SH2 region of SOCS-1. SOCS-1 therefore plays an important role in the early phase of crosstalk 
between the GR and cytokine signalling (Haffner et al., 2008).  
Besides cytosolic located GR, non-genomic GR effects are also triggered by, or at least 
dependent on membrane bound GR (mGR). The mGR is able to interact with other signalling 
pathways such as G-protein coupled receptors (GPCRs) (De Bosscher et al., 2000). An example 
of this is the interaction of mGR and the gonadotropin releasing hormone receptor (GnRHR) at 







1.2.4 GR pro-inflammatory actions 
 
Glucocorticoids have been shown to cause pro-inflammatory effects, which seems to contrast 
with their anti-inflammatory actions (Wiegers et al., 1998). Interaction between the 
glucocorticoid receptor signalling pathway and inflammatory signalling pathways, such as the 
TNFR signalling pathway, has been shown to cause the co-regulation of many genes, with 
several of them being cooperatively expressed (Lannan et al., 2012). Microarray data showed 
that glucocorticoids could induce the expression of chemokines, cytokines and other immune-
related genes of immune cells (Galon et al., 2002). Stimulation with GCs has also been shown 
to increase the expression of cytokine receptors, which correlates with an enhanced cytokine 
effect on target cells (Almawi et al., 1996). Pre-treatment of macrophages with GCs was shown 
to induce cytokine overexpression and NFκB activation, further highlighting the paradoxical 
crosstalk between GCs and pro-inflammatory signalling pathways (Smyth et al., 2004). 
Glucocorticoids may be positively regulating inflammation to prepare the immune system for 
a quick and effective response to pathogens. It is vital for the pathogen, or cause of 
inflammation, to be swiftly removed, so an immediate repression of the immune response by 
glucocorticoids would be unfavourable. Therefore, not only is it important for GCs to not 
repress the inflammatory response immediately, but specifically GCs should not repress the 
innate immune response before the cause of inflammation is resolved. GCs therefore have the 
ability to positively interact initially with the innate immune system and Th1 responses, while 
inhibiting the adaptive immunity, and Th2 responses, until homeostasis is restored (Galon et 
al., 2002). 
 
A previous study showed more than 800 genes were co-regulated significantly by dex and TNFα 
in microarray data, with over 300 of them being involved in inflammatory diseases (Lannan et 
al., 2012). In the same study above, were also able to show that genes co-regulated by TNFα 
and dex could also be synergistically upregulated, such as serpinA3, SAA1 and SAA2. Synergism 
is defined as a response where the combined effect of two signals is greater than the sum of 
the individual responses, where each signal on its own is able to induce a response (Chou, 
2006). If the overall level of the combined effect is not greater than the sum, then the signals 




not induce a response on its own, but does increase the response of the second signal, this is 
referred to as priming or sensitizing.  
CCL20 is a chemoattractant for neutrophils and Th17 cells and was shown to be expressed by 
the GC budesonide in human bronchial epithelial cells (Zijlstra et al., 2014). Budesonide was 
also able to modulate the TNFα mediated expression of CCL20 when co-stimulated, 
highlighting a crosstalk between the signalling pathways. Wang et al. (1997) showed that dex 
can induce CCL20 expression in human bronchial epithelial cells, and that this most likely was 
a direct effect, as they co-stimulated the cells with cycloheximide, an inhibitor of de novo 
protein synthesis, to minimize potential secondary effects. Zijlstra et al. (2014) showed that 
GCs were able to modulate and enhance the TNFα induced expression of CCL20. In other 
words, co-stimulation with TNFα and GCs resulted in an overall level of CCL20 expression 
greater than either TNFα, or the GC alone.  
 
 
1.3 CCL20  
 
1.3.1 CCL20 structure, receptor and promoter 
 
C-C motif chemokine ligand 20 (CCL20), alternatively named macrophage inflammatory 
protein-3alpha, liver and activation-regulated chemokine (LARC), Exodus or SCYA20 is a 
chemoattractive cytokine that has been shown to be expressed by a variety of cell and tissue 
types such as PBMCs, epithelial cells, lung tissue and liver tissue (Rossi et al., 1997). The mature 
CCL20 protein comprises of 70 amino acid residues, with a molecular weight of 8kDa, with 
cysteine residues at locations characteristic of CC chemokines (Hieshima et al., 1997). CCL20 
has been shown to have low levels of sequence similarity with other CC chemokines, while X-
ray crystallography has shown that its structure is very similar to those of other CC chemokines 
(Hoover et al., 2002; Yoshie et al., 1997). 
  
The full length, exon-encoded CCL20 mRNA is 821 nucleotides in length and contains 









Figure 1.4. CCL20 mRNA exons and base pair length.  
The CCL20 mRNA transcript is 3199 bp, with the translation start site (ATG) is marked at position 59 in 
the 5’ to 3’ direction as described by (Hromas et al., 1997). 
 
The receptor for CCL20 is the G-protein coupled receptor (GPCR) chemokine receptor 6 (CCR6) 
which is expressed on leukocytes such as T helper cells, monocytes, macrophages, and 
dendritic cells (DC) (Kucharzik et al., 2002; Liao et al., 1999). CCR6 plays a specific role in the 
induction of DC towards epithelial cells due to the invasion of pathogens and antigens (Dieu-
Nosjean et al., 1999). Recent studies have also shown CCR6 to be a specific marker for Th17 
cells and regulatory T cells distinguishing them from other helper T cells (Hirota et al., 2007). 
CCR6 has also been shown to be expressed on leukaemia and pancreatic cancer cells, however 
the exact role of the receptor on cancer cells is unknown (Imaizumi et al., 2002; Kleeff et al., 
1999). CCL20 has the highest affinity for CCR6, with β-defensins-1 and -2 having much lower 
affinities (Williams, 2004; D. Yang et al., 1999). 
 
 
1.3.2 CCL20 Promoter and Binding Transcription Factors 
 
Analysis of the CCL20 promoter region upstream of the transcription start site has shown 
putative binding sites for NFκB, C/EBP, AP-1, c-Ets, Sp1, STAT1 and GR within its first 700 base 
pairs (Table 1) (Hieshima et al., 1997; Moore et al., 2010; Sugita et al., 2002). The CCL20 
promoter contains a putative GR binding site (J. H. Kwon et al., 2003). ChIP analysis determined 










Table 1. Transcription factor binding sites on the putative CCL20 promoter determined in silico. 
Putative transcription factors from -647 to +58 base pairs of the putative CCL20 promoter (Hieshima et 
al., 1997; Moore et al., 2010; Sugita et al., 2002). 
 
 
NFκB is a transcription factor protein complex, which plays a key role in the regulation of 
immune function genes (Gilmore, 2006). The NFκB complex contains the proteins p50 (NFkB1), 
p52 (NFkB2), p65 (RelA), c-Rel, and RelB (Baeuerle et al., 1996). NFκB is a primary transcription 
factor, and therefore resides in the cytoplasm in an inactive state, sequestered by a family of 
proteins called inhibitors of κB (IκB) (S. Ghosh et al., 1990). IκB is generally phosphorylated 
upon NFκB activation, leading to NFκB dissociation and nuclear translocation. Upon activation 
by pro-inflammatory ligands, the canonical NFκB p65/p50 subunit binds to NFκB promoter sites 
and causes transcriptional activation. NFκB also causes the transcriptional increase of its own 
inhibitor IκB. This creates a negative feedback loop, where the increased activity of NFκB 
causes its inhibition within the cytoplasm (Brown et al., 1993). Phosphorylation of NFκB is also 
rapidly induced upon activation, with p65/RelA phosphorylation at S529 serving as a biomarker 




signalling cascades and cellular kinases such as protein kinase C (PKC). Mitogen-activated 
protein kinases (MAPKs) such as PKC has been shown to cause the dissociation of the NFκB/IκB 
complex (S. Ghosh et al., 1990). 
Specific binding of the p50/p65 heterodimer, and p65/p65 homodimer has been shown to bind 
to the CCL20 NFκB site in human cells (Fujiie et al., 2001). Other possible TFs involved in CCL20 
regulation are members of the forkhead box-containing protein O subfamily-1 (FOXO1). FOXO1 
affects CCL20 gene expression in an NFκB dependent manner. TNFα-mediated CCL20 
expression is enhanced by FOXO1 overexpression, and attenuated by FOXO1 silencing, 
although only when a functioning NFκB binding site is present. Furthermore, FOXO1 is not 
predicted to have a binding site on the CCL20 promoter (Miao et al., 2012).  
 
Activator protein 1 (AP-1) is a transcription factor protein dimer involved in the control of basal 
and inducible gene expression. The heterodimer consists of Jun and Fos family proteins and 
binds to TPA-responsive elements (TREs) on the DNA (Hess et al., 2004). The Jun protein family, 
also known as c-Jun, consists of JunB and JunD, and the Fos protein family, also known as c-
Fos, consists of FosB, Fra-1 and Fra-2 (Karin, 1995). Jun proteins can bind either as a homo- or 
heterodimer, while the Fos proteins can only form a heterodimer with Jun. Jun/Fos 
heterodimers, however, bind more strongly than Jun homodimers to DNA. Despite the high 
level of similarities between Jun and Fos proteins, differences in sequence specificity suggest 
differential dimeric complex regulation of distinct subsets of AP-1 regulated genes (Angel et 
al., 1991). AP-1 is activated by a variety of cell signals in response to growth factors, 
inflammation and carcinogens. As expected for a transcription factor involved in many 
processes, AP-1 is tightly regulated via its expression, and post-translational modifications such 
as phosphorylation (Boyle et al., 1991). MAPKs have been shown to be involved in AP-1 
signalling, with PKC−/− in mice preventing AP-1 activity via the T-cell receptor (TCR) (Sun et al., 
2000). 
 
(TCR)-induced activation of AP-1 has also been shown to have both positive and negative 
effects on the activity of other transcription factors, such as NFκB and the GR (Jonat et al., 
1990; Xiao et al., 2004). While, classically, AP-1 and the GR negatively affect each other’s 




cell types, with c-Jun homodimers in composite sites, or via tethering directly to AP-1 (Herrlich, 
2001).  
 
Signal transducers and activators of transcription (STAT) proteins are transcription factors that 
play an important role in the immune response and were discovered due to their key 
involvement in IFN signalling (Darnell Jr et al., 1994). The members of the STAT family are 
STAT1, STAT2, STAT3, STAT4, STAT5 (STAT5A and STAT5B), and STAT6. STAT1 activation has 
been shown to be involved in both the synergistic activation, and suppression of gene 
expression, and therefore serves as an important member in crosstalk between signal 
transduction pathways (Ramana et al., 2000). STAT1 is phosphorylated within the cytoplasm 
at S727 by receptor-associated Janus protein tyrosine kinases (Jaks), before nuclear 
translocation, and binds to the DNA as a homodimer (X. Zhu et al., 1997).  
A putative binding site for STAT1 is predicted within the CCL20 promoter, with STAT1 silencing 
causing a reduction in the expression of CCL20 mRNA (Moore et al., 2010). Constitutively STAT1 
expression in A549 cells was shown to cause an increase in CCL20 gene expression in rat 
pancreatic cells (Li et al., 2007).  
 
CCAAT/enhancer-binding proteins (C/EBPs) are a subfamily of the basic leucine zipper domain 
transcription factors. C/EBPs play an important role in the immune response, cellular 
differentiation and in metabolism (Ramji et al., 2002). The members of the C/EBP family are 
C/EBPα, C/EBPβ, C/EBPδ, C/EBPγ, C/EBPε, and C/EBPζ. C/EBPβ deficient mice have been shown 
to have a compromised immune system, highlighting the importance of the transcription factor 
in the immune response (Poli, 1998). Both C/EBPβ and C/EBPδ have been shown to be induced 
by glucocorticoid stimulation (Roesler, 2001). Glucocorticoid activation of C/EBPβ has been 
shown to involve the phosphorylation at T235, which increases the binding affinity of the 
transcription factor, and has been shown to be independent of C/EBPβ de novo protein 
expression (Berg et al., 2005; Ramji et al., 2002). Of particular interest, C/EBPβ has been shown 
to directly interact with other transcription factors, such as NFκB, AP-1 and the GR, on the 
promoter of genes (Hsu et al., 1994; Johansson-Haque et al., 2008; LeClair et al., 1992). C/EBP 
has been shown to be a critical regulator of CCL20, being able to bind and induce expression 
of CCL20 mRNA (Sperling et al., 2012). The GR and C/EBP proteins can activate transcription 




cause post-translationally modifications of C/EBP proteins (Fig 1.5B), or cause the upregulation 
of C/EBP proteins (Fig 1.5C) (Ramos et al., 1996). C/EBPα and C/EBPβ are specifically implicated 
in the GC mediated induction of genes via C/EBP DNA binding regions (CCAAT box motifs) (Sai 




Figure 1.5. Possible mechanisms which GR could positively interact with the C/EBP to cause the induction 
of CCL20. 
Transcription via composite response elements and protein-protein interactions (A), post-
translationally modifications of C/EBPβ (B) and via the upregulation of C/EBPβ (C) (Ramos et al., 1996). 
 
 
It has also been reported that the specificity protein 1 (Sp1)-binding site within the CCL20 
promoter is involved in regulating basal CCL20 transcription (J. H. Kwon et al., 2003). 
Overexpression of Sp1, and site-directed mutagenesis of the Sp1 binding site caused 
respectively caused an increase and decrease of the activation of a CCL20 promoter-reporter 
system in Caco-2 cells (J. H. Kwon et al., 2003). Kwon et al. also demonstrated that the E26 
transformation-specific (Ets) transcription factor, epithelium-specific Ets 1 (ESE-1) is essential 






1.3.3 Biological Functions of CCL20 
 
As a chemokine, CCL20 has been shown to be a strong chemoattractant for lymphocytes, 
dendritic cells, NK cells and neutrophils (Schutyser et al., 2003). CCL20 can be expressed by a 
large variety of cells such as epithelial and endothelial cells; lung, liver, pancreatic and cells of 
the reproductive system (Giannini et al., 2002; Hieshima et al., 1997). This expression can be 
constitutive, while increased CCL20 expression can be elicited by microbial factors such as 
lipopolysaccharide (LPS) and by inflammatory factors such as tumour necrosis factor α (TNFα), 
causing migration of targeted leukocytes to the local inflammatory site (Schutyser et al., 2000). 
Leukocyte responsiveness to CCL20 has been shown to depend on cell-type, sub-type, 
maturation and/or differentiation of the leukocyte. 
Immature dendritic cells, including Langerhans cells (LC) have been shown to be responsive to 
CCL20, with a chemotaxis occurring (Charbonnier et al., 1999; Dieu et al., 1998). Functional 
CCR6 protein expression has been observed in CD34+ HPC-derived immature DC, as well as in 
immature monocyte-derived DC, and CCL20 acted as a chemoattractant for these cells (Power 
et al., 1997; Vanbervliet et al., 2002). Furthermore, CCL20 is a potent chemoattractant for 
freshly isolated, ex vivo LC, however, once these cells were matured with GM-CSF and TNFα, 
CCR6 expression, and CCL20 responsiveness decreased (Charbonnier et al., 1999). Langerhans 
cells are present in the epidermis, and therefore target microbial antigens, becoming antigen-
presenting cells (Katz et al., 1979).  
CCL20 is a strong chemoattractant for T-lymphocytes (Th17), with CD4+ cells expressing higher 
levels of CCR6 than CD8+ T-cells (Liao et al., 1999). These CD4+ Th17 cells and neutrophils are 
important for the innate immune system, and the immediate migration of these cells to the 
site of infection is vital as they are one of the first responders and are a hallmark for acute 
inflammation (Ouyang et al., 2008).  CCL20 is also a chemoattractant for both memory and 
naïve B-lymphocytes (Krzysiek et al., 2000). 
 
CCL20 is also implicated in the progression of pathological processes and negative side effects 
of drug use. Inflammation mediated by Th17 cells has been implicated in GC insensitivity in 
asthma patients (Zijlstra et al., 2014). Increased CCL20 expression due to GCs has been 




been shown to express CCL20, with higher amounts expressed in cells with colon and 
inflammatory bowel disease compared to normal cells, thereby increasing the leukocytes to 
their surface (J. Kwon et al., 2002). An increase of leukocytes in the colon has been associated 
with colon cancer (Y.-J. Lee et al., 2006). Increased CCL20 production is implicated in the 
progression of rheumatoid arthritis, and in immunopathogenesis of the necroinflammatory 
response in the liver (A. Lee et al., 2014; Shimizu et al., 2001). Furthermore, increased CCL20 
expression at mucosal epithelial barriers is implicated in an increase in HIV-1 acquisition. This 
is due to an increased presence of Langerhans cells (LCs) in mucosal epithelia, such as of the 
cervix and oral cavity, which become targets for HIV-1 acquisition (Giannini et al., 2002; 
Hosokawa et al., 2005; Miller, 2007). Therefore, understanding the mechanisms in CCL20 




Aims and Hypotheses 
 
The aim of this study was to examine the mechanisms of crosstalk of the GR and inflammatory 
inducing signals on the pro-inflammatory gene CCL20. In particular, the study focuses on the 
expression of CCL20 mRNA in epithelial cell lines using tissue culture techniques. It has 
previously been shown that glucocorticoids, which are primarily noted for their anti-
inflammatory actions, are able to induce the expression of pro-inflammatory chemokines and 
cytokines (Galon et al., 2002). Zijlstra et al. (2014) showed that the expression of the pro-
inflammatory chemokine CCL20 was induced by glucocorticoids in human bronchial epithelial 
cells. Furthermore, co-stimulation with glucocorticoids and the pro-inflammatory ligand TNFα 
caused an enhanced, modulatory effect on the expression of CCL20. The mechanisms of how 
glucocorticoids increase CCL20 expression and how they can crosstalk and modulate the 
induction of CCL20 by mediators of pro-inflammation have not been determined. Therefore, 
this study seeks to examine some of the potential mechanisms of this regulation. Due to 
CCL20’s role in immune function, knowledge of the different inflammatory inducing signalling 
pathways and their crosstalk with glucocorticoids can provide more information on the 
mechanisms of CCL20 regulation. More specifically, this project investigated the following 
hypothesis; the pro-inflammatory chemokine CCL20 can be regulated in a variety of cell types 
by glucocorticoids and pro-inflammatory ligands, with crosstalk between them seen with co-
treatment. The following aims/questions are addressed in this project; 
 
i) Can the pro-inflammatory chemokine CCL20 be upregulated in a variety of cell 
types by inflammatory inducing signals, and by glucocorticoids? 
 
ii) Does co-stimulation of cells with inflammatory inducing ligands and glucocorticoids 
have an enhanced, modulatory effect in CCL20 expression? 
 






iv) Does the observed increase of CCL20 expression occur at the level of transcription 
and, therefore, can glucocorticoids and inflammatory inducing ligands activate the 
putative CCL20 promoter on a reporter construct? 
 
v) Is the NFκB binding site on the CCL20 putative promoter integral in CCL20 
induction? 
 
CCL20 is expressed in a wide variety of cells and tissue types, both constitutively and via 
induction by a broad spectrum of inducers. Besides its role in maintaining homeostasis of the 
immune system, CCL20 has been implicated in pathological processes, especially at epithelial 
surfaces (Schutyser et al., 2000). Therefore, an understanding of CCL20 regulation, and its 
induction by GCs and inflammatory inducers is important in understanding its role in mediating 








Chapter 2: Materials and Methods 
 
2.1 Cell Culture 
 
Human epithelial cervical cancer cells (HeLa), African Green monkey kidney fibroblast cells 
(COS-1) and adenocarcinomic human alveolar basal epithelial cells (A549) were purchased 
from America Type Culture Collection (ATCC, USA). Human osteosarcoma cells (U2OS) were 
purchased from Sigma-Aldrich, South Africa. The cell lines mentioned above were cultured in 
75 cm2 flasks (Greiner Bio-one International, Austria) in Dulbecco’s modified Eagle’s medium 
(DMEM) (Sigma-Aldrich, South Africa) supplemented with 10% (v/v) fetal bovine serum 
(Highveld Biological, South Africa), 100 IU/mL penicillin and 100 μg/mL streptomycin (Gibco, 
Invitrogen, UK). 
 
Human endocervical cells immortalized with human papillomavirus 16 E6/E7 (End1) cell line 
(Fichorova et al., 1997) was obtained from Dr Fichorova, Brigham & Women’s Hospital, Boston, 
USA. End1 cells were cultured in 75 cm2 flasks (Greiner Bio-one International, Austria) in 
keratinocyte serum-free medium (KSFM) (Sigma-Aldrich, South Africa) supplemented with the 
provided keratinocyte growth supplement, 100 U/mL penicillin and 100 μg /mL streptomycin 
(Gibco, Invitrogen, UK). 
 
All cells were maintained at 37°C in a 5% CO2 incubator. Cells were passaged with 0.25% 
trypsin/ 0.1% EDTA in PBS (Highveld Biological, South Africa). To stop the trypsinization, the 
process was neutralization with medium [DMEM (Sigma-Aldrich, South Africa), 10% (v/v) calf 
serum (Highveld Biological, South Africa), 100 U/mL penicillin and 100 μg /mL streptomycin 
(Gibco, Invitrogen, UK)]. The cell lines were regularly tested for mycoplasma infection by 








2.2 Compounds and Antibodies 
 
Dexamethasone (dex) (D4902), tumour necrosis factor α (TNFα) (T7539), phorbol 12-myristate 
13-acetate (PMA) (P1585), Mifepristone (M8046) (RU486), and lipopolysaccharide (LPS) 
(L2630) were from Sigma-Aldrich, South Africa. Interferon γ (IFNγ) (01-A0060-0100) was from 
ORF Genetics. The primary antibodies for GR (H-300; sc-8992), GAPDH (0411; sc-47724), c-Jun 
(H-79; sc-1694), c-Fos (K-25; sc-253) were from Santa Cruz Biotechnology, USA. The secondary 
antibodies anti-mouse HRP (sc-2005) and anti-rabbit HRP (sc-2313) were also from Santa Cruz 




The pTAT-GRE-E1b-luc (TAT-GRE) plasmid containing the E1b promoter and two copies of rat 
GRE (Sui et al., 1999), was a kind gift from Dr G. Jenster (Erasmus University of Rotterdam, 
Rotterdam, Netherlands). The pGL2-MIP-3α plasmid (the –871/+58 fragment of the human 
CCL20 promoter) and pGL2-MIP-3α/mκB plasmid (like the pGL2-MIP-3α plasmid, but with the 
NF-κB-binding site (nt –92 to –82) mutated through site-directed mutagenesis) (Imaizumi et 
al., 2002) were a kind gift from Prof. N. Mori (University Graduate School of Medical Sciences, 
Nagasaki, Japan). The pcDNA3 (empty vector) plasmid was obtained from Invitrogen, UK. The 
steroid receptor plasmid pcDNA3-hGR (GR) (Verhoog N, 2011) was obtained from Prof. D.W. 
Ray (University of Manchester, UK). 
 
 
2.4 Plasmid Transformation and Preparation 
 
Plasmids were prepared by transforming them in competent E. coli DH5α cells, while the pGL2-
MIP-3α and the pGL2-MIP-3α/mκB plasmids were transformed into E. coli JM109 cells 
(Promega). Transformation was done as according to the heat shock method of Sambrook et 
al. (Sambrook et al., 1989). Briefly, 50 ng of plasmid DNA was added to 100 µl of competent 
cells and mixed, without vortexing. The cells were incubated for 20 mins on ice, heat shocked 




tryptone, 0.5% (w/v) yeast extract, 0.05% (w/v) NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 mM 
glucose) was added, and the mixture was incubated at 37°C for 60 mins, with shaking. Of the 
mixture, 200 µl was plated on an LB-AMP selection plate (1% (w/v) tryptone, 0.5% yeast 
extract, 1% NaCl and 1.5% agarose containing 50 µg/mL of ampicillin) overnight at 37°C. A 
single colony was inoculated in 5 ml LB medium (1% (w/v) tryptone, 0.5% yeast extract and 1% 
NaCl) with ampicillin (100 ng/µl), and incubated at 37°C for 8 hours. To purify the culture, 1 ml 
was added to the Promega Pureyield Plasmid Midi-prep kit (Promega Corp., USA), according to 
the manufacturer’s instructions. DNA was quantified using a NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies), while the integrity and purity of the plasmids 




2.5 Transient Transfection of Cells and Luciferase Assay 
 
For the promoter-reporter luciferase assay, HeLa cells were plated in 48-well plates (Sigma 
Aldrich, RSA) at a density of 5.0 x 104 cells per well. The cells were transiently transfected the 
following day with either (250 ng DNA per well) pGL2-MIP3α or pGL2-MIP3α/κBm using 
XtremeGene9 (Roche Diagnostics, RSA) and incubated for 24 hours. Cells were washed once 
with PBS on day three, and treated with 100 nM dex, 20 ng/mL TNFα, 20 ng/mL PMA, 5 ng/mL 
LPS, or 20 ng/mL IFNγ, in serum free DMEM medium for 24 hours. The cells were harvested by 
washing twice with PBS and lysed in 50 µl 1X Reporter lysis buffer (Promega, Madison, WI, 
USA). Luciferase activity from the lysates was measured using the Luciferase Assay System 
(Promega, Madison, WI, USA) and a Modulus microplate luminometer (Turner Biosystems, 
Sunnyvale, CA, USA). Luciferase values were normalized to protein content per well using the 









2.5 RNA Isolation and cDNA Synthesis 
 
HeLa cells were plated at 5.0 x10 4 cells per well, End1 cells at 2.0 x 105 per well, and both COS1 
and U2OS at 1.5 x 105 cells per well in 12 well plates (Greiner Bio-one International, Austria). 
24 hours later (and 48 hours later for HeLa), cells were treated with test compounds or vehicle 
for another 24 hours. Thereafter, cells were washed with PBS, and Total RNA was isolated from 
cells using TRI Reagent® (Sigma-Aldrich, South Africa) according to the manufacturer's 
instructions.  
The isolated RNA was quantified using a NanoDrop® ND-1000 Spectrophotometer (NanoDrop 
Technologies) and the integrity of the RNA was confirmed by the appearance of 18S and 28S 
ribosomal bands on denaturing agarose gel electrophoresis. Briefly, 15 µl sample loading buffer 
(12 % (v/v) DEPC water, 5 % (v/v) bromophenol blue solution, 7 % (v/v) glycerol, 10 % (v/v) 10X 
Morpholinopropanesulfonic acid (MOPS) buffer (0.2 M MOPS in DEPC water, 0.05 M sodium 
acetate and 0.01 M ethylenediaminetetra-acetic acid  (EDTA)), 17 % (v/v) 12.3 M formaldehyde 
and 49 % (v/v) formamide) with 20 µg/mL ethidium bromide (EtBr) was added to 0.5 µg RNA, 
then electrophoresed on a 0.8 % agarose gel (70 % (v/v) DEPC water, 10 % (v/v) 10X MOPS 
buffer and 20% (v/v) formaldehyde) at 70 V for 45 mins.  
Total RNA (500 ng) was reverse transcribed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, USA) according to the manufacturer's instructions. 
 
 
2.6 Real-Time quantitative Reverse Transcription PCR (qRT-PCR) 
 
Equal volumes of synthesised cDNA were used for real-time qRT-PCR using the Sensi-Mix SYBR 
Green I system (Celtic Diagnostics, South Africa), or the FastStart Essential DNA Green Master 
system (Roche Applied Science, South Africa), and the Rotor-gene, RG-3000A (Corbett 
Research). Gene expression was measured using specific primer sets as described in Table 2 
with GAPDH serving as the ‘housekeeping’ gene. The 20 µl PCR reaction mix contained 10 µl 
Sensi-Mix SYBR Green I, or the FastStart Essential DNA Green Master, 1 µl cDNA, 1 µl sense 
primer, 1 µl anti-sense primer and 7 µl PCR grade, RNA-free water. The PCR protocol was as 




72°C for 10 sec. To confirm the amplicon generated was the one desired, melting curve analysis 
and gel electrophoresis was performed on each sample. A standard curve was generated to 
determine the efficiency of each primer set, and this was used to determine relative transcript 
levels by the method described by Pfaffl et al. 2002 (Supp Fig 5). GAPDH was used to normalise 
transcript levels. 
 
Table 2. Primer sequences and operating information. 





CCL20 CGAAGCAACTTTGACTGCTG Forward 58°C 500 nM (Miao et 
al., 2012) CAAGTCCAGTGAGGCACAAA Reverse 58°C 500 nM 
GAPDH TGAACGGGAAGCTCACTGG Forward 58°C 500 nM (Ishibashi 
et al., 
2003) 
TGTCAGTTGATAAAACCGCTGCC Reverse 58°C 500 nM 
IL6 TCTCCACAAGCGCCTTCG Forward 60°C 250 nM (Wolf et 





2.7 SDS-PAGE and Western Blotting 
 
HeLa cells were plated at 5.0 x 104 cells per well, End1 cells at 2.0 x 105 per well, and both COS1 
and U2OS at 1.5 x 105 cells per well in 12 well plates (Greiner Bio-one International, Austria). 
24 hours later (and 48 hours later for HeLa), cells were treated with test compounds or vehicle 
for another 24 hours. Thereafter, cells were washed once with PBS and lysed with 50 µl 2X SDS 
sample buffer (5 X SDS sample buffer: 100 mM Tris-Cl pH 6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 
2% ß-mercaptoethanol and 0.1% (w/v) bromophenol-blue) and boiled for 10 min at 100 °C. 
Equal amounts of the harvested samples were loaded on an 8% SDS polyacrylamide gel (PAGE) 
and separated at 120 V using a BioRad Mini Protean® II electrophoresis cell and a running 




proteins were subsequently electroblotted for 60 min, with a constant current set at 180 mA, 
onto a Hybond™ ECL™ nitrocellulose membrane (GE healthcare, Germany), contained within 
a BioRad Mini Trans-blot® cell, according to manufacturer’s instructions, and submerged in ice-
cold transfer buffer (25 mM Tris, 200 mM glycine, 10% (v/v) methanol). The membranes were 
blocked in 4% enhanced chemiluminescence (ECL) blocking solution (Amersham) and 
reconstituted in a Tris-buffered Saline and Tween-20 (TBS-T) solution (50 mM Tris, 150 mM 
NaCl and 0.1% (v/v) Tween) at pH 75 (Sambrook et al., 1989). Monoclonal primary antibodies 
were diluted in 4% (ECL) blocking solution. Primary antibody solutions were added to the 
membrane and incubated overnight at 4°C on an orbital shaker at 65 rpm. After incubation, 
excess primary antibody was removed by washing the membrane for 15 min in 10 mL TBS-T at 
room temperature, followed by 2 similar TBS-T washes for 5 min each. Secondary HRP 
conjugated antibody, diluted in 5% (w/v) fat-free milk powder reconstituted in (TBS-T) solution 
was added to the membrane and incubated for 60 min at 65 rpm at room temperature. The 
membrane was washed again, as previously described, to remove excess secondary antibodies. 
Proteins were visualised using Pierce® ECL western blotting substrate (Thermo Scientific, South 
Africa), according to the manufacturer’s protocol, and Hyperfilm MP high performance 
autoradiography film (Amersham, South Africa). Bands were scanned and quantified using the 
ImageJ software (National Institutes of Health). 
 
Table 3. Dilutions of antibodies used in western blot analysis. 
Antibody Dilution Secondary antibody 
GAPDH 1 : 20000 Mouse (1 : 5000) 
GR 1 : 4000 Rabbit (1 : 10000) 
HSP90 1 : 1000 Mouse (1 : 5000) 












2.8 Statistical Analysis 
 
Statistical analyses were performed with GraphPad Prism software (version 5 and version 7) 
with different letters representing statistical significance by one-way ANOVA, with Tukey's 
Multiple Comparison Test, or a two-way ANOVA with Tukey’s Post-Test with significance either 
denoted with different letters, or by #, ##, ### or ### indicating P< 0.05, P< 0.001, P<0.0005 
or P< 0.0001, respectively (Tukey, 1949). Statistical significance by a t-test is denoted by *, **, 
*** or **** to indicate P< 0.05, P< 0.001, P<0.0005 or P< 0.0001, respectively. The statistical 
tests performed for each experiment are indicated in the respective figure legends. Both a one-
way ANOVA and t-test was performed on the results obtained in the results throughout. While 
a t-test is more likely to show a significant difference between different conditions, it is more 
likely to produce a Type I error. Therefore, a one-way, or two-way ANOVA was used to control 
for this error as it is more stringent. However, although the t-test is more likely to produce 
Type I error, this does not necessarily mean that the statistical significance produced by this 





Chapter 3: Results 
 
3.1 Dex and TNFα can induce CCL20 expression, and modulate each other’s 
induction in a cell-specific manner  
 
It has previously been shown in the lung epithelial 16HBE cell line that a glucocorticoid could 
induce the expression of CCL20 mRNA, and that this expression could be potentiated when co-
stimulated with the mediator of inflammation TNFα (Zijlstra et al., 2014). To investigate 
whether CCL20 mRNA induction and potentiation can occur in different cell lines, HeLa, End1, 
COS1, U2OS and A549 cells were stimulated with 100 nM dex, 20 ng/mL TNFα, or a 
combination of both for 24 hours in serum-free media, and CCL20 mRNA was measured using 
qRT-PCR, with fold induction measured relative to vehicle. The primer efficiencies for CCL20 
and GAPDH primers were determined by generating standard curves (Supp Fig 5). In the HeLa 
cell line dex and TNFα were able to induce a 258- and 293-fold increase in CCL20 mRNA 
expression, respectively, compared to the vehicle (Fig 3.1A). Co-stimulation with dex and TNFα 
resulted in a significant 5177-fold increase in CCL20 mRNA expression, which was significantly 
different to that of TNFα alone indicating apparent synergism in the HeLa cell line (Fig 3.1A bar 
4).  
 
The previous experiment was repeated in the End1, A549, U2OS and COS1 cell lines. In the 
End1 cell line dex and TNFα were each able to induce a statistically significant 1.66- and 48.9-
fold increase in CCL20 mRNA expression; with co-stimulation not causing an increase in 
induction compared to the TNFα response alone, which resulted in a 49-fold increase in CCL20 
mRNA (Fig 3.1B). In the A549 cell line, dex and TNFα were able to induce statistically significant 
4.22- and 1029-fold increases respectively in CCL20 mRNA expression; while co-stimulation 
with dex and TNFα did not cause an increase in induction compared to the TNFα response 
alone, with a 763-fold induction of CCL20 mRNA compared to the vehicle (Fig 3.1C). However, 
there was a high degree of error in the A549 result. In the U2OS cell line, dex and TNFα were 
able to induce 4.16- and 19.7-fold increase, respectively compared to vehicle although this was 
not statistically significant most likely due to experimental error (Fig 3.1D). Co-stimulation with 




statistically significant 37.7-fold increase in CCL20 mRNA compared to the vehicle (Fig 3.1D bar 
4). The COS1 result was similar to the U2OS, with no significance seen most likely due to 
experimental error.  Dex and TNFα caused 1.77- and 22.6-fold increases, respectively, in CCL20 






Figure 3.1. Dex and TNFα highly induce the expression of CCL20 mRNA expression and co-stimulation has 
an apparent synergistic response. 
End1 (A), A549 (B), HeLa (C), U2OS (D) and COS1 (E) cells were seeded into 12-well plates at a density 
of 5 x 105, 5 x 104, 5 x 105, 2.5 x 105, 2.5 x 105, cells/well, respectively and incubated for 48 hours. Cells 
were treated with 100 nM dex, 20 ng/mL TNFα, or a combination of both, as stated, in serum-free 
DMEM. Thereafter, the cells were washed twice with PBS and harvested for total RNA with TRIzol® and 




normalised to GAPDH mRNA expression. Relative gene expression was normalized to basal activity 
(vehicle) in order to obtain relative fold expression. Graphs represent pooled results of at least three 
independent experiments and are plotted as a mean. Statistical analysis was carried out using GraphPad 
Prism™ software, with same letters representing no statistical significance and different letters 
representing statistical significance by one-way ANOVA, with Tukey's Multiple Comparison Test. 
Statistical significance by a t-test is denoted by *, **, *** or **** to indicate P< 0.05, P< 0.001, P<0.0005 
or P< 0.0001, respectively. 
 
 
Different levels of transcription factors between the various cell lines may contribute to the 
different responses seen. To examine whether the total levels of GR and p65 differed between 
the cell lines, HeLa (Fig 3.2A lane 1 and 2), End1 (Fig 3.2A lane 3 and 4), A549 (Fig 3.2A lane 5 
and 6), U2OS (Fig 3.2A lane 7 and 8) and COS1 cell lines were probed for GR, p65 and GAPDH 
under basal conditions with two independent experiments per cell line. Results were scanned 
and quantified with GR (Fig 3.2B) and p65 (Fig 3.2C) relative to GAPDH protein levels as 
determined via western blotting and band density.  
 
The HeLa and End1 cell lines have the highest levels of GR protein. U2OS and COS1 cell lines 
have very low levels of GR protein as expected. Statistical significance is only seen between the 
HeLa and End1 cell lines compared to the U2OS and COS1 cell lines (Fig 3.2B compare lanes 1 
and 2 to lanes 4 and 5). The levels of total p65 were very similar in each cell line, with no 





Figure 3.2. Western blot analyses of GR and p65 under basal (vehicle) conditions, scanned and quantified. 
HeLa (lane 1 and 2), Hend1 (lanes 2 and 3), A549 (lanes 5 and 6), U2OS (lanes 7 and 8) and COS1 (lanes 
9 and 10) cells were probed to examine basal GR and p65 protein levels with each replicate an 
independent experiment (n=2). Equal amounts of cell lysates were loaded on an 8% SDS-PAGE gel, 
transferred onto nitrocellulose membrane and probed with antibodies to GR, p65 and GAPDH (loading 
control). Band density was quantified using ImageJ™ Software with GR (B) and p65 (C) relative to 
GAPDH.  Statistical analysis was carried out using GraphPad Prism™ software and ImageJ software. 
Statistical significance by a t-test is denoted by *, **, *** or **** to indicate P< 0.05, P< 0.001, P<0.0005 
or P< 0.0001, respectively. 
 
 
TNFα and dex are able to induce CCL20 with statistical significance in the HeLa, End1 and A549 
cell lines, with co-stimulation enhancing the effect with statistical significance in the HeLa cell 
lines (Fig 3.1). The differences in CCL20 expression between the cell lines when stimulated with 
dex may be due to the differences in total GR. The total p65 levels did not vary between the 
cell lines. 
 
3.2 Other pro-inflammatory ligands besides TNFα can induce the expression of 





To further investigate the crosstalk between dex and ligands that induce inflammation and 
therefore different signalling pathways, the PKC activator PMA, the Th1 cytokine IFNγ, and the 
bacterial cell wall component LPS were used instead of TNFα. PMA was used as it acts directly 
on PKC, which is involved in inflammatory signal transduction pathways, while IFNγ was used 
as it is specifically part of the Th1 immune response, and has been shown not to activate NFκB. 
LPS was used as it is exogenous, unlike the other ligands, and is of bacterial origin. HeLa cells 
were stimulated with 100 nM dex, a signal of inflammation (5 ng/mL PMA, 20 ng/mL IFNγ, 5 
ng/mL LPS) or a combination of both for 24 hours in serum-free media (Fig 3.3A-C), and CCL20 
mRNA was measured using qRT-PCR, with fold induction measured relative to vehicle. 
Stimulation with dex increased CCL20 mRNA by 253-, 290- or 227.6-fold (Fig 3.3A-C bar 2), 
while stimulation with PMA, IFNγ and LPS increased CCL20 mRNA by 85.9-, 2.61- or 4.62-fold, 
respectively (Fig 3.3A-C bar 3). Co-stimulation with dex and PMA, IFNγ or LPS increased CCL20 







Figure 3.3. The pro-inflammatory ligands PMA, IFN and LPS, and dex can induce the expression of CCL20 
mRNA expression and can potentiate the dex response in the HeLa cell line.  
HeLa cells were seeded into 12-well plates at a density of 5 x 105 cells/well and incubated for 48 hours. 
Cells were treated with 100 nM dex, and/or 5 ng/mL PMA (A), 20 ng/mL IFNγ (B), 5 ng/mL LPS (C), or a 
combination of both, as stated, in serum-free DMEM. Thereafter, the cells were washed twice with PBS 
and harvested for total RNA with TRIzol® and 500 ng RNA was reverse-transcribed. CCL20 mRNA 
expression was measured by qRT-PCR and normalised to GAPDH mRNA expression. Relative gene 
expression was normalized to basal activity (vehicle) in order to obtain relative fold expression. Graphs 
represent pooled results of at least three independent experiments and are plotted as mean +/- SEM. 
Statistical analysis was carried out using GraphPad Prism™ software, with different letters representing 
statistical significance by one-way ANOVA, with Tukey's Multiple Comparison Test. Statistical 
significance by a t-test is denoted by *, **, *** or **** to indicate P< 0.05, P< 0.001, P<0.0005 or P< 
0.0001, respectively. 
 
The different ligands were also used on A549 cells as above (Supp Fig 2).  
The different ligands used to stimulate the cells may affect the levels of protein involved in the 
signalling pathways that are a part of CCL20 regulation. To examine whether stimulation with 




absence or presence of 100 nM dex, and either 20 ng/mL TNFα, 5 ng/mL PMA, 20 ng/mL IFNγ 
or 5 ng/mL LPS for 24 hours in serum-free media. Fig 3.4A and B represent two independent 
experiments. Results were scanned and quantified for GR (Fig 3.4C) and p65 (Fig 3.4D) relative 
to GAPDH protein levels as determined via western blotting and band density. Stimulation with 
dex appeared to cause GR turnover, which was expected (Chapter 1.2), with a significant 
difference seen in in the TNFα compared to TNFα and dex result (Fig 3.4C compare lanes 9 and 




Figure 3.4. Western blot analyses of GR and p65 under various cellular conditions, scanned and 
quantified. 
HeLa cells were seeded into 12-well plates at a density of 5 x 105 cells/well and incubated for 48 hours. 
Cells were treated with either 20 ng/mL TNFα, 20 ng/mL PMA, 5 ng/mL LPS, or 20 ng/mL IFNγ, in the 
presence or absence of 100 nM dex, as stated, in serum-free DMEM. Equal amounts of cell lysates were 
loaded on an 8% SDS-PAGE gel, transferred onto nitrocellulose membrane and probed with antibodies 
to GR, p65 and GAPDH (loading control). A and B are 2 independent experiments. The quantified levels 
of GR (C) and p65 (D) protein levels are shown for A and B n=2. Statistical analysis was carried out using 
GraphPad Prism™ software and ImageJ software. Statistical significance by a t-test is denoted by *, **, 







Taken together, all four inflammatory inducers, TNFα, PMA, IFNγ and LPS, are able to induce 
CCL20 expression in the HeLa cell line (Fig 3.1 and 3.3). Furthermore, all inflammatory inducers 
are able to potentiate the dex response. Total GR levels did not change due to the inflammatory 
inducers used, but GR turnover was seen when cells were stimulated with dex as expected. 
Total p65 levels were not altered between different conditions. This indicates that there is 
crosstalk between the GR signalling pathway, and that of the inflammatory inducers used. 
 
 
3.3 The GR is required for the dex response on CCL20 mRNA, with GR inhibition 
resulting in the loss of the modulatory effects of co-stimulation with pro-
inflammatory ligands  
 
To confirm whether the dex-induced increase of CCL20 mRNA is mediated via the GR, the GR 
antagonist RU486 was used to inhibit the receptor (Philibert et al., 1990). Although RU486 also 
antagonizes the progesterone receptor (PR), it has been shown that HeLa cells do not express 
the PR (Bourgeois et al., 1984). The potential of the unliganded GR to modulate the CCL20 
mRNA induction of the pro-inflammatory ligands was also investigated.  
 
HeLa cells were stimulated with 100 nM dex, 20 ng/mL TNFα, or a combination of both for 24 
hours in serum-free media, in the presence or absence of 1nM RU486. CCL20 mRNA was 
measured using qRT-PCR, with fold induction measured relative to vehicle. On average, 
stimulation with RU486 increased basal CCL20 expression about 10-fold relative to vehicle (Fig 
3.5A-D bar 2). The dex-induced expression of CCL20 mRNA was significantly reduced to basal 
levels in the presence of RU486 from 266.9- to 9.12-fold, 199.6- to 9.12-fold, 199.6- to 14.7-
fold and 199.6- to 9.12-fold (Fig 3.5A-D, compare bars 3 and 4). RU486 significantly repressed 
the apparent synergy between dex and TNFα, PMA, IFNγ and LPS from 5637- to 671-fold, 1867- 






Figure 3.5. The GR is required for the dex effect on CCL20 mRNA levels, as the GR inhibitor RU486 
abolishes the response and the dex modulation of TNFα, PMA, IFNγ and LPS.  
HeLa cells were seeded into 12-well plates at a density of 5 x 105 cells/well and incubated for 48 hours. 
Cells were treated with 100 nM dex 20 ng/mL and/or TNFα (A), and/or 5 ng/mL PMA (B), 20 ng/mL IFNγ 
(C), 5 ng/mL LPS (D), as stated in the presence or absence of 100 nM dex, or 100 nM dex alone. These 
conditions were further co-stimulated in the presence, or absence of 1 nM RU486, as stated, in serum-
free DMEM for 24 hours. Statistical analysis was carried out using GraphPad Prism™ software, with 
Statistical significance by one-way ANOVA, with Tukey's Multiple Comparison Test denoted by #, ##, 
###, or #### to indicate P< 0.05, P< 0.001, P<0.0005 or P< 0.0001, respectively. Statistical significance 




The GR is required for the dex-induced increase of CCL20, with inhibition of the receptor with 
RU486 resulting in a loss of the dex response. Inhibition of the GR did not affect the 







3.4 The pro-inflammatory ligands can potentiate the dex transactivation of the 
CCL20 promoter-reporter construct pGL2-MIP3α-LUC 
 
Previous results have shown that both dex and the pro-inflammatory ligands; TNFα, PMA and 
LPS can induce endogenous CCL20 mRNA expression. Dex can also modulate the induction of 
CCL20 when co-stimulated with the pro-inflammatory ligands. To examine whether there is 
crosstalk between dex and the pro-inflammatory ligands on a minimal promoter, the pGL2-
MIP3α-LUC plasmid reporter construct was used. To confirm the correct plasmid was used, a 
restriction enzyme digest was performed (Fig 3.6). The fragment sizes were confirmed to be 
similar to what was expected (Table 4). The reporter plasmid has the putative CCL20 promoter, 
-871 base pairs upstream, and +58 base pairs downstream of the transcription start site, and 
therefore only contains certain cis-regulatory elements (Sugita et al., 2002). Knowledge of 
which transcription binding sites are present, and how dex and the different mediators of 
inflammation affect its transcription will help elucidate the different mechanisms of CCL20 










Figure 3.6. Restriction enzyme digest of the pGL2-MIP3α-LUC and pGL2-MIP3α/κBm-LUC promoter-
reporter constructs to confirm plasmid identity. 
Digested plasmid fragments of the pGL2-MIP3α-LUC and pGL2-MIP3α/κBm-LUC were separated via 
electrophoresis on a 0.8% agarose gel. 3 μl of a 1kb molecular weight marker (Fermentas Life Science 
O’GeneRuler™) was used in lane 1 to confirm plasmid fragment sizes. 
 
 
Table 4. Expected and obtained band sizes after restriction enzyme digest of pGL2-MIP3α-LUC and pGL2-
MIP3α/κBm-LUC promoter-reporter constructs (Imaizumi et al., 2002). 
Lane Expected fragment size(s) (bp) Obtained fragment size(s) (bp) 
1 MW ladder 
2 < 6629 9500, 8500, 3750 and 2500 
3 6629  7000 and 2500 
4 5693 and 936  5500, 2500 and 950  
5 < 6629  9500, 8500, 3750 and 2500 
6 6629  9500, 7500 and 2500 
7 5693 and 936  5500, 2500 and 950 
 
 
HeLa cells were transfected with the pGL2-MIP3α-LUC plasmid reporter construct for 24 hours 
before stimulating with 100 nM dex, a signal of inflammation (20 ng/mL TNFα, 5 ng/mL PMA, 




3.7A-D). As shown in Figure 3.7A, stimulation with dex and TNFα caused a statistically 
significant 2.6-fold and 9.7-fold increase of transcriptional activity, respectively, of the 
luciferase reporter gene (Fig 3.7A, bar 2 and 3). Co-stimulation with dex and TNFα significantly 
increased activation to 20.5-fold relative to vehicle (Fig 3.7A, bar 4). PMA caused a statistically 
significant 13-fold increase of transcriptional activity (Fig 3.7B, bar 3), while co-stimulation with 
dex and PMA increased activation, statistically significant, to 31.5-fold relative to vehicle (Fig 
3.7B, bar 4). IFNγ repressed the basal activity on the promoter, with a statistically significant, 
0.632-fold reduction relative to vehicle. (Fig 3.7C, bar 3). Dex relieved this repression, with a 
1.28-fold induction of the promoter relative to vehicle when co-stimulated with IFNγ (Fig 3.7C, 
bar 4). LPS was unable to activate the pGL2-MIP3α-LUC reporter (Fig 3.7D, bar 3), although did 








Figure 3.7. The pro-inflammatory ligands can potentiate the dex transactivation of the CCL20 promoter-
reporter construct pGL2-MIP3α-LUC. 
HeLa cells were seeded into 48-well plates at a density of 5 x 105 cells/well. The following day, the cells 
were transiently transfected with 250 ng pGL2-MIP3α-LUC DNA. Cells were treated with 100 nM dex, 
20 ng/mL TNFα, or a combination of both, as stated, in serum-free DMEM. Total cells were harvested, 
and RLUs measured via a luminometer and normalised to respective protein content, determined with 
a Bradford assay. Promoter activity was normalized to basal activity (vehicle) equal to 1, in order to 
obtain relative fold expression. Graphs represent pooled results of at least three independent 
experiments and are plotted as a mean +/- SEM. Statistical analysis was carried out using GraphPad 
Prism™ software, with different letters representing statistical significance by one-way ANOVA, with 
Tukey's Multiple Comparison Test. Statistical significance by a t-test is denoted by *, **, *** or **** to 
indicate P< 0.05, P< 0.001, P<0.0005 or P< 0.0001, respectively. 
 
 
Dex was shown to induce the pGL2-MIP3α-LUC promoter as it did to the endogenous gene. 
TNFα and PMA were able to induce promoter, with an apparent potentiation of the dex 




although it was shown to potentiate the dex response. Differing from the result seen on the 
endogenous promoter, IFNγ repressed the basal and dex mediated pGL2-MIP3α-LUC activity. 
This highlights the different transcription factor binding sites used between the ligands. 
 
 
3.5 Mutation of the NFκB binding site on the CCL20 promoter-reporter construct 
affects the activation by dex and pro-inflammatory ligands compared to the wild-
type promoter 
 
The NFκB region has been shown to be important for TNFα induced activation of the CCL20 
promoter (Sugita et al., 2002). To determine whether the NFκB site of the CCL20 promoter is 
required for CCL20 regulation by dex and mediators of inflammation, the same reporter 
plasmid, with a mutated NFκB response element was used (Imaizumi et al., 2002). HeLa cells 
were transfected with the pGL2-MIP3α-LUC reporter construct, and in parallel the NFκB 
mutated pGL2-MIP3α/κBm-LUC reporter construct for 24 hours.  
 
To confirm the correct plasmid was used, a restriction enzyme digest was performed (Fig 3.6). 
The fragment sizes were confirmed to be similar to what was expected (Table 4). Cells were 
stimulated with 100 nM dex, and either 20 ng/mL TNFα (A), 5 ng/mL PMA (B), 20 ng/mL IFNγ 
(C) or 5 ng/mL LPS (D) in combination or alone (Fig 3.8A-D). The overall levels of luciferase 
transcribed were lower in the mutated plasmid compared to the wild type, with a significant 
decrease in basal activation relative to the pGL2-MIP3α-LUC (Fig 3.8B-D).  This highlights the 
importance of NFκB for CCL20 activation. The dex activation of the promoter appeared to 
increase relative to vehicle, with a significant increase when the basal/vehicle level of 
transcription of the pGL2-MIP3α-LUC and the pGL2-MIP3α/κBm-LUC reporter is set to 1 (Supp 
Fig 4). A significant increase in the dex mediated induction of the mutated promoter construct 
compared to the wild-type is seen in Supplementary Figure 4. TNFα, LPS and IFNγ were unable 
to transactivate the mutated promoter (Supp Fig 4A-C). The mediators of inflammation were 
also unable to potentiate the dex mediated activation of the mutated CCL20 promoter. IFNγ 
was unable to transactivate either the wild-type or mutated CCL20 promoter and inhibited the 






Figure 3.8. Mutation of the NFκB binding site on the CCL20 promoter-reporter construct causes a 
reduction of activation by the pro-inflammatory ligands and dex compared to the wild-type promoter. 
HeLa cells were seeded into 48-well plates at a density of 5 x 105 cells/well. The following day, the cells 
were transiently transfected with either 250 ng pGL2-MIP3α-LUC or pGL2-MIP3α/κBm-LUC reporter 
construct. Cells were treated with either 20 ng/mL TNFα (A), 20 ng/mL PMA (B) 5 ng/mL LPS (C), or 20 
ng/mL IFNγ (D), in the presence or absence of 100 nM dex, as stated, in serum-free DMEM. Total cells 
were harvested, and RLUs measured via a luminometer and normalised to protein content, determined 
with a Bradford assay. Graphs represent pooled results of at least three independent experiments and 
are plotted as mean +/- SEM. Statistical analysis was carried out using GraphPad Prism™ software, with 
Statistical significance by one-way ANOVA, with Tukey's Multiple Comparison Test denoted by #, ##, 
###, or #### to indicate P< 0.05, P< 0.001, P<0.0005 or P< 0.0001, respectively. Statistical significance 




Mutation of the NFκB binding site reduces the overall induction of the putative CCL20, and 
therefore highlights the importance of the transcription factor in the induction. TNFα and PMA 
are unable to induce the mutated NFκB promoter, and along with LPS are unable to potentiate 
the dex response. IFNγ still represses the mutated promoter. The dex-induced activation of the 
promoter is not via the NFκB binding site, as it is still able to activate the mutated promoter 









4.1.1 GCs and TNFα Increase CCL20 expression in a cell-specific manner 
 
Zijlstra et al. (2014) showed that GCs can induce CCL20 mRNA expression in primary bronchial 
cells and a human bronchial epithelial cell line. Therefore, the current study investigated 
whether the synthetic GC, dex, can induce CCL20 RNA expression in cells other than bronchial 
epithelial cells.  
Research in the expression of CCL20 in other cell types besides those of the lung is important 
for the understanding of the effects of CCL20 in diseases and their progression throughout the 
body. It is known that epithelial cells of the female genital tract can express CCL20 (Cremel et 
al., 2006). This is significant as it has been suggested CCL20 may be involved in an increase of 
HIV-1 acquisition (Cameron et al., 2010). The End1 and HeLa cell lines were, therefore, used as 
in vitro models of the female genital tract, the main site of HIV-1 transmission. Furthermore, 
because HeLa cells are cancerous in origin they are routinely used as an in vitro model of 
human cervical cancer. CCL20 has also been implicated in the progression of rheumatoid 
arthritis, with bone tissue shown to express the chemokine (A. Lee et al., 2014). The U2OS cell 
line is a bone osteosarcoma epithelial cell line, and was used to investigate the mechanisms of 
CCL20 regulation in the bone. A549 are cancerous human alveolar epithelial cells and are a 
useful model in studying the regulation of gene expression in airways epithelial cells. A previous 
study reported that dex suppresses TNF-induced CCL20 expression in A549 cells (Lannan et al., 
2012). However, it remains unclear whether dex can regulate basal CCL20 expression in this 
cell line. Further research into the mechanisms of CCL20 regulation in these cell types, and 
whether GCs may exacerbate the pathology of these tissues via increasing CCL20 expression, 
is required, as well as whether this has implications for diseases and their progression. To 
further try and elucidate the mechanisms of CCL20 regulation by GCs and pro-inflammatory 
ligands, COS-1 were used. This is a fibroblast-like cell line derived from African Green monkey 




COS-1 cells express CCL20, however African Green monkeys have been shown to express 
CCL20 in lung samples (Smits et al., 2011).  
 
 
In Figure 3.1, dex was shown to significantly induce CCL20 mRNA expression in the End1, A549 
and HeLa cell lines, with a 1.66-fold, 4.22-fold and 258-fold increase, respectively, with respect 
to basal (vehicle) expression (Fig 3.1A, B and C). Dex, however, was not able to cause a 
significant increase in CCL20 in the U2OS and COS1 cells lines (Fig 3.1D and E).  
 
GCs, such as the endogenously expressed cortisol, or synthetic GCs such as dex are used to 
suppress the inflammatory response and prevent the detrimental effects of chronic 
inflammation such as tissue damage (Lawrence et al., 2007). While GCs are important in 
suppressing inflammation, they have also been implicated in pro-inflammatory effects. This 
may be to prepare the immune system for a quick and efficient response to pathogens with 
acute exposure and suppress the immune system with chronic exposure to GCs (Cruz-Topete 
et al., 2015). It may be important for GCs to still chemoattract leukocytes to the site of 
inflammation by inducing CCL20 expression, while also suppressing the expression of pro-
inflammatory genes. This may be to prevent the site of inflammation becoming 
immunodeficient, which could increase the chances of a secondary infection occurring (Cutolo 
et al., 2008). 
 
The differences in CCL20 induction in the End1, A549 and HeLa cell lines, which expressed 
CCL20 when stimulated with dex, could be due to a variety of reasons. Intrinsic differences 
between the cell lines may be a reason for why there are differences in the level of CCL20 
expression. For instance, dex has been reported to upregulate basal as well as TNF/LPS-induced 
expression of CCL20 in human bronchial epithelial BEA-2B cell line, but not in A549 (Zijlstra et 
al., 2014; Lannan et al., 2014). The results presented herein show that the cell lines differ in 
level of expression of the GR. Hence, some cell lines may be more sensitive to treatment with 
dex than others.  However, although HeLa and End 1 cells had similar levels of GR expression, 
the level of the response elicited by dex was much higher in HeLa than in End 1. This suggests 
that different mechanisms other than GC sensitivity may be vital for the upregulation of basal 




expressed in human kidney tissues, but microarray data has shown treatment with GCs reduces 
its expression (Cheng et al., 2013). Therefore, it is likely that GCs also reduce the expression of 
CCL20 in the simian, COS-1 cell line. It is important to note that tissue culture work with cell 
lines will not always reflect what occurs in vivo as many other factors may not be present, and 
the cells may react differently to stimuli as they have been immortalised. 
 
Cell-to-cell variations in levels of proteins such as enzymes, kinases and transcription factors 
can affect the expression levels of genes. The differences in CCL20 induction in the various cell 
lines due to stimulation with dex may, therefore, be due to differences in the relative GR 
protein levels. To examine whether the expression pattern of the GR varied between the 
different cell types, western blotting was performed. Cell lysates were probed for GR (Fig 3.2A). 
The U2OS and COS1 cell lines had visibly and statistically lower levels of GR than the others and 
may therefore be why dex is unable to induce CCL20 in these cell lines (Fig 3.1D and E). End1, 
A549, HeLa and U2OS cells are all cell lines of epithelial origin and COS1 cells are fibroblast, 
kidney cells. Epithelial cells, and specifically End1, A549 and HeLa cells, serve as cellular barriers 
to the outside environment and are, therefore, one of the first lines of defence against external 
pathogens, while the U2OS osteosarcoma cells  may not respond due the gene being packaged 
into inactive chromatin. It may be essential for cells of epithelial tissue to excrete chemokines 
even when GCs are present to allow for neutrophils to be present in the area of high risk. 
Therefore, GCs are not necessarily immunosuppressive on all genes, at least with the respect 
to the innate immune system, and especially within epithelial tissues (Busillo et al., 2013).  
 
During inflammation TNFα is secreted by leukocytes and plays a major role in a systemic 
inflammatory response. Zijlstra et al. (2014) showed that TNFα caused an increase of 
expression of CCL20 in BEA-2B cells. This result was confirmed in Fig 3.1A, with TNFα causing 
about a 1000-fold increase in CCL20 mRNA expression, compared to vehicle. The TNFα 
mediated induction of CCL20 in the various cell lines, relative to vehicle, also showed variation 
as seen with dex stimulation. TNFα was able to cause a statistically significant increase of about 
200-fold in the HeLa cell line and about 40-fold in the End1 cell line, while only causing less 





A possible reason for the greater CCL20 response due to TNFα between the A549 cells and the 
HeLa and End1 cells may be due to intrinsic differences between the cell lines. As with the 
differences in GR protein levels seen between the cell lines being a possible contributing factor 
to the dex responses seen, differences in TNFα level of induction may be due to differences in 
amounts and activation of other transcription factors, and proteins involved. The TNFα 
pathway is involved in the activation of NFκB, therefore, the protein levels of the p65 subunit 
was probed. However, no differences, were seen between the different cell lines (Fig 3.2A). 
Although there were no differences seen in total p65 levels between the cell lines in Fig 3.2C, 
this does not exclude NFκB from playing a role in the differences in the TNFα mediated 
responses. As only total p65 levels were probed for, it is possible that there are changes in the 
activated/phosphorylated form of p65. Cells may also have different levels of IκB kinase (IKK), 
which, when activated, phosphorylated IκB, causing the release of NFκB to bind to the DNA 
(Karin, 1999). Therefore, a greater amount of IKK may allow for more active NFκB without 




4.1.2 The pro-inflammatory stimuli provided by PMA, IFNγ and LPS can induce 
CCL20 expression 
 
To examine whether CCL20 gene expression can be regulated by other inflammatory ligands, 
and therefore different signalling pathways, other inflammatory molecules and mediators of 
inflammation were used to stimulate HeLa cells. TNFα, PMA, IFNγ and LPS can cause the 
activation of AP-1, while IFNγ has been shown to be unable to activate NFκB which the others 
can, and instead activate STAT1, which the others cannot (Chapter 1.3.2).  
 
TNFα induces its induction of genes via the TNF receptor type 1 and 2 (TNFR1/2), activating 
mitogen-activated protein kinases (MAPKs) amongst other members in its signalling pathway. 
Activation of CCL20 by TNFα therefore may involve the activation of many members in its 
signalling pathway including MAPKs. To examine the effects of specifically activating the 




cells. PMA activates protein kinase C (PKC), which is a MAPK that plays an important role in 
several signal transduction cascades (Ali et al., 2016).  
 
Stimulation with IFNγ allowed for the activation of a different signalling pathway which does 
not activate NFκB as the other pro-inflammatory molecules do. This may, therefore, provide 
mechanistic insights into the regulation of CCL20 (Andreakos et al., 2004). IFNγ is an 
endogenous molecule expressed in humans, and therefore would provide insights to CCL20 
expression due to molecules expressed by Th1 leukocytes during an inflammatory response 
(Schoenborn et al., 2007). 
 
Inflammatory signals which induce the expression of chemokines can also originate from 
exogenous sources, such as from pathogens. Bacterial infections may require the recruitment 
of macrophages to phagocytose the pathogens.  Cells can recognise components of bacterial 
cells walls using pattern recognition receptors (PRRs), such as toll-like receptor 4 (TLR4), which 
recognises lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative 
bacteria (Takeuchi et al., 2010). 
 
All pro-inflammatory inducers could induce a significant increase in CCL20 mRNA in the HeLa 
cell line (Figure 3.3), although the relative induction differed greatly between them. This is with 
accordance of CCL20 being a pro-inflammatory chemokine, therefore it has been shown to be 
induced by the pro-inflammatory stimuli used. Table 1 shows that the putative CCL20 promoter 
contains binding sites for transcription factors known to be activated by the inflammatory 
inducers used, namely NFκB, AP-1, and STAT1. The differences in the relative magnitude of 
induction compared to vehicle for each inflammatory signal may be due to other proteins and 
transcription factors activated by each signalling pathway. For example, LPS and TNFα 
phosphorylate IKK via transforming growth factor β-activated kinase 1 (TAK1) and NFκB-
inducing kinase (NIK), respectively (C. Wang et al., 2001; Zarnegar et al., 2008). These different 
kinases may have different affinities for IKK, leading to different levels of activation of NFκB. It 
should be stressed however that the signalling pathways of the various ligands used are 
complex and can interact with various proteins within the cell. These cannot only affect the 
activation of various transcription factors, but also, for example, the stability of the mRNA 






4.1.3 Co-stimulation with GCs and pro-inflammatory stimuli can enhance CCL20 
expression 
 
Having established that dex could induce CCL20 mRNA expression in the HeLa cell lines, it was 
determined what effects co-stimulation with TNFα would have. As seen in Figure 3.1A, dex and 
TNFα produced over a 4000-fold increase in CCL20 mRNA expression relative to basal in the 
HeLa cell line. This is much greater than the combination of the individual responses, showing 
apparent synergism on CCL20 expression. To confirm whether this is true synergy, a Chou-
Talalay method can be used (Chou, 2010).  
 
This apparent synergism, or modulation of the TNFα response of CCL20 expression, however, 
did not occur in the A549 cell line. Interesting to note is Lannan et al. (2012) showed co-
stimulation of A549 cells with dex and TNFα caused a strong downregulation of CCL20. In the 
study of Lannan et al. (2012), however, study however used 1/10th the amount of dex (10 nM), 
500X more TNFα (10 μg/mL) and 1/4 the stimulation time (6 h) than used in this study, and this 
may underlie the differences seen on CCL20 expression.  
The apparent synergism or potentiation was not seen in the End1, COS1 and U2OS cell lines. 
This shows a cell-specific effect of modulation between dex and TNFα of CCL20 expression. 
These cell-specific differences may be due to different levels of receptors, members of the 
signalling pathway, or transcription factors (Gutierrez-Arcelus et al., 2015).  
 
Having demonstrated the cell-specific synergistic upregulation of CCL20 mRNA between TNFα 
and dex under these conditions, the effects of co-stimulation with dex and other inflammatory 
ligands were investigated in the HeLa cell line. When HeLa cells were co-stimulated with dex 
and PMA, the level of CCL20 expression was significantly higher than when stimulated with 
either ligand alone (Fig 3.3A). The potentiation was also seen in the co-stimulation with LPS 
and IFNγ in the presence of dex, although, because the expression caused by the inflammatory 




sensitize, the dex response (Fig 3.3C and B). These results show clear crosstalk between the 
dex and the pro-inflammatory ligands TNFα, PMA, IFNγ and LPS.  
 
A considerable amount previous research has focused on GC and inflammatory responses in 
the lungs, specifically looking at drug resistance (Giembycz et al., 2015; R. Newton et al., 2010). 
To examine whether other pro-inflammatory ligands could cause a synergistic upregulation of 
CCL20 in A549 cells when co-stimulated with dex, cells were stimulated with PMA, IFNγ and 
LPS as they were in the HeLa cell lines. No synergy was statistically seen with co-stimulation, 
although there did seem to be an apparent enhancement of the CCL20 induction with co-
stimulation compared to each ligand on its own (Supp Fig 2). The differences in the responses 
to the pro-inflammatory ligands in the HeLa cells compared to the A549 cells, with the latter 
always having higher responses (compare Fig 3.1 with Supp Fig 2), highlights the cell- and 
ligand-specific effects on CCL20 induction. 
 
The differences in the expression of CCL20 by the different inflammatory inducers may be due 
to the effects they have on the levels of certain transcription factors involved in their signalling 
pathways. The various inflammatory inducers did not cause any changes in GR levels in the 
HeLa cell line when compared to the vehicle, or each other (Fig 3.7A and B). There appeared 
to be a trend with dex reducing the GR levels in the presence or absence of inflammatory 
inducers, with only the TNFα condition with and without dex showing a significant drop in GR 
protein levels. This is an expected result as GC stimulation causes GR turnover (Chapter 
1.2.2.3). There were no changes in the p65 levels under any of the conditions, but as explained 
in Chapter 4.1.1, this does not necessarily exclude the importance of p65 and NFκB in 
explaining the observed differences (Fig 3.7A and C). 
 
The upregulation of pro-inflammatory genes by dex in the absence or presence of pro-
inflammatory ligands suggests that GCs prepare the immune system for a quick and efficient 
response to acute exposure to pathogens (Cruz-Topete & Cidlowski, 2015). Previous studies 
have shown that treating HeLa and A549 cells with dex induces the expression of TLR2 thereby 
priming the cells towards TLR2-specific immune responses (Sakai et al., 2004; Imasato et al., 
2004). Compared to controls, cells primed with dex have been shown to express more pro-




al., 2011).  Therefore, the pro-inflammatory effects of GCs may exacerbate immune responses 
or may prime and prepare the immune system respond promptly and clear invading pathogens 
through   the expression of chemokines such as CCL20.  
 
4.1.4 The GR is required for GC mediated induction of CCL20 and crosstalk with 
pro-inflammatory stimuli  
 
Having established that dex can induce CCL20 mRNA expression, and that there is crosstalk 
between dex and pro-inflammatory inducers, it was next determined whether this occurred in 
a GR-dependent manner by using the GR inhibitor RU486. Although RU486 is also a potent 
antagonist of the progesterone receptor (PR), HeLa cells do not express endogenous PR. 
Therefore, it can be assumed any inhibitory effects of RU486 are via the GR (Giangrande et al., 
1997). Stimulation of cells with RU486 completely abolished the dex induced expression of 
CCL20, while having no effect on the expression due to the inflammatory inducers TNFα, PMA, 
IFNγ and LPS (Fig 3.5A-D and Supp Fig 3A-D). This would be expected as RU486 is specific for 
only the GR in these cells. This shows that the GR is required for the dex mediated induction of 
CCL20 mRNA, and dex does not induce CCL20 via other methods. Furthermore, without the 
ability to activate the GR, dex was unable to potentiate or crosstalk with the inflammatory 
inducers (Fig 3.5 and Supp Fig 3). This furthermore shows that the mechanism for dex to 
crosstalk with inflammatory inducers is via the GR. The loss of statistical significance in CCL20 
expression, relative to vehicle, in TNFα, PMA, IFNγ and LPS stimulated cells, in the presence of 
RU486, may due to error introduced into the experiments (Supp Fig 3). 
 
Interesting to note is that stimulation with RU486 caused an increase in basal/vehicle 
expression of CCL20, although this difference was not statistically significant. This may indicate 
that the unliganded, inactivated GR may a have slight repressive effect on basal CCL20 
expression. These results indicate that the active GR is not only required for the dex response, 
but also for the crosstalk between dex and the inducers of inflammation. The GR is therefore 









4.1.5 The putative CCL20 promoter is activated by GCs and some pro-inflammatory 
ligands on a reporter construct 
 
Using a CCL20 promoter-reporter construct can reveal which regions on the promoter of CCL20 
are critical for its induction, eliminate any effects of chromatin remodelling necessary for 
endogenous CCL20 induction, and remove any crosstalk between GCs and the mediators of 
inflammation that occur post-transcriptionally. The pGL2-MIP-3α construct used has the 
promoter region, from -871 to +58 base pairs upstream of the CCL20 promoter, attached to 
the luciferase gene as the reporter (Imaizumi et al., 2002). Because the reporter construct only 
contains a section of the putative CCL20 promoter, regulatory insights can be determined from 
the identification of transcription factor binding sites. Fig 4.2 shows putative transcription 
factor binding sites determined in silico, showing the differences between the endogenous 
promoter from -1381 base pairs, and the pGL2-MIP-3α construct. Overall, the fold induction 
compared to vehicle in all stimulated conditions was lower than that observed on the 
endogenous gene (Fig 3.2 compared to Fig 3.4). This suggest that other cis elements not 
included in the reporter plasmid construct may be involved in CCL20 mRNA expression in the 
presence of the ligands. In addition, the cells may be limiting the synthesis of luciferase protein 
to prevent cell toxicity, which may restrict the ability of the luciferase assay to measure the 
activity of the promoter in the presence of the ligands. The differences in the response elicited 
by dex in the absence or presence of pro-inflammatory ligands on the endogenous gene and 
reporter plasmid may also be due to that some transcription factors play a role in recruiting 
other transcription factors to the promoters of target genes. For example, C/EBP and AP-1 have 
been shown to make the chromatin more accessibility to the GR, even where there are no 
GREs (Grøntved et al., 2013; Biddie et al., 2011). As shown in Fig 4.2, the endogenous CCL20 
promoter has an extra C/EBP site compared to the reporter plasmid construct. This suggests 
that the GR, activated by dex, might interact with this and other such sites which are lacking in 
the reporter construct, to transactivate the endogenous CCL20 promoter in the absence or 








Figure 4.1. Putative regulatory transcription factor binding sites for the pGL2-MIP-3α construct and the 
endogenous CCL20 promoter region. 
The putative regulatory transcription factor binding sites for the pGL2-MIP-3α construct are compared 
to the endogenous CCL20 promoter from -1381 base pairs upstream to the start of transcription site. 
The binding sites were determined in silico (Heinemeyer et al., 1998). 
 
 
Dex was shown to significantly induce the putative promoter of the pGL2-MIP-3α luciferase 
vector (Fig 3.4A-D). This therefore supports the possibility of a GRE within the putative CCL20 
promoter. It is also possible for the GR to tether onto other transcription factors, such C/EBP 
to induce the promoter (Louw-du Toit et al., 2014; Sai et al., 2008). The pGL2-MIP-3α luciferase 
vector with the putative promoter was significantly induced in the HeLa cell line by dex and 
TNFα. Co-stimulation with dex and TNFα further increased the induction of the promoter, 
although this increase was only statistically significant compared to dex alone and not TNFα 
(Fig 3.4A). However, the result does closely mirror the result seen in on endogenous CCL20, 
and lack of significance may be due to experimental error. PMA, like TNFα, was shown to 
induce the reporter construct (Fig 3.4B). LPS, however, was not able to statistically significantly 
induce the construct, with a 1.63-fold increase (Fig 3.4D). This, however, was approaching 
significance with a p value of 0.0674.  This suggests that the transcription factor binding sites 
necessary for the TNFα, PMA and LPS mediated activation of CCL20, and its crosstalk with the 
GR are present within the pGL2-MIP-3α promoter region, and are most likely NFκB, C/EBP and 





Surprisingly, IFNγ appeared to repress the activity of the pGL2-MIP-3α promoter, statistically 
significantly reducing the basal induction to 0.633-fold relative to vehicle (Fig 3.4C). The STAT 
binding site is not present in the pGL2-MIP-3α construct, while it is predicted in the 
endogenous putative promoter (Fig 4.2). The STAT binding site, therefore, may be required for 
IFNγ mediated induction, and potentiation of the dex response on the endogenous promoter, 
as the response is lost in the construct. Furthermore, the repressive effects of IFNγ on CCL20 
are most likely not via the STAT binding site and may occur via another mechanism. Some 
studies have shown that both STAT and NFκB are involved in the IFNγ signalling pathway, with 
an NFκB loop positioned downstream of STAT (Ramana et al., 2002; van Boxel-Dezaire et al., 
2007). Thus, it is possible that STAT is needed to induce the synthesis of a protein that activates 
NFκB or alternatively STAT and NFκB on the CCL20 promoter. Because STAT is absent from the 
pGL2-MIP-3α construct, such interactions between STAT and NFκB would no longer be possible 
and hence the activity of the pGL2-MIP-3α construct may then be repressed in the presence 
of IFNγ.       
 
 
4.1.6 The NFκB binding site on the CCL20 promoter is important for CCL20 
induction 
 
NFκB plays a key role in the regulation of the immune response, and transcriptional activation 
of pro-inflammatory genes (Gilmore, 2006). The NFκB site has been shown to be necessary for 
the induction of pro-inflammatory genes when induced by signals of inflammation (Xie et al., 
1994). To further investigate the mechanisms of CCL20 induction by the GR and pro-
inflammatory signalling pathways, the CCL20 reporter construct pGL2-MIP-3α/mκB was used. 
This construct is the same as the pGL2-MIP-3α construct, but with the NF-κB-binding site (–92 
to –82) mutated through site-directed mutagenesis. NFκB would, therefore, be unable to bind 
and be involved in the activation of the CCL20 promoter in this plasmid. Compared to the 
relative light units measured in the basal level of expression in the presence of vehicle, the 
mutated NFκB binding site construct (pGL2-MIP-3α/mκB reporter construct) has a reduced 
activity compared to the wild type promoter (pGL2-MIP-3α reporter construct) (Fig 3.5A-D). 




Although mutation of the NFκB site causes a drop in the overall induction compared to wild 
type promoter, the promoter is still inducible, however, only weakly. When the graphs are re-
plotted with both the vehicles of the wild type and NFκB mutated promoter set to 1, the dex-
induced activation increases from 2-fold to 5-fold (Supp Fig 4). This increase in the dex 
response relative to their respective vehicles suggests that while dex can increase CCL20 
induction via binding to sites such as the GRE and potentially C/EBP or AP-1, the dex response 
is repressed via NFκB. The repressive action of the GR on NFκB also occurs under basal 
conditions as, seen with an increase in the induction by the inflammatory ligands on 
endogenous promoter when cells were stimulated with the GR inhibitor RU486 (Fig 3.5B). 
Therefore, the dex response on CCL20 induction is most likely due to the net effect of;  
 
i) activated GR binding directly to the GRE on the CCL20 putative promoter, and/or 
the positive interactions between the GR and other transcription factors such as 
C/EBPβ or AP-1, thereby increasing CCL20,  
ii) the classical mechanisms of NFκB/GR mechanisms of co-repression and,  
iii) NFκB activating the CCL20 promoter, allowing for relatively higher levels of 
induction. 
 
Therefore, while the NFκB binding site is important for the overall magnitude of the reporter 
construct induction; it is not necessary for the dex mediated induction. Furthermore, GR does 
not interfere with the DNA binding properties of NFκB (Han et al., 2001). 
TNFα and PMA are apparently unable to induce the mutated reporter, therefore, it cannot be 
ascertained whether they can induce the mutated reporter, especially in the case of PMA 
(Supp. Fig 4B). It thus appears that TNFα and PMA require the NFκB binding site on the reporter 
construct for CCL20 activation. IFNγ still repressed the basal/vehicle induction of the CCL20 on 
the mutated promoter, it would appear that the repressive effects are, therefore, not via the 
NFκB binding site (Fig 3.5C and Supp).  
 
In summary (Fig 4.2), dex, via the GR, can induce both the endogenous, pGL2-MIP-3α and 
pGL2-MIP-3α/mκB CCL20 promoter. Kwon et al. (2003) determined in silico that the CCL20 
promoter contained a GRE, the DNA target sequence for GR binding. It is therefore likely that 




pro-inflammatory cytokine, although counter-intuitive, can be supported by the pro-
inflammatory effects of GC on the innate immune system, and especially within epithelial cells 
(Busillo et al., 2013; Cruz-Topete et al., 2015). Furthermore, So et al. (2007) described a GRE 
binding site within an intron 4409 base pairs downstream of the transcription start site via a 
ChIP assay, but the regulatory properties of this GRE have not been extensively studied. Other 
mechanism for the GR to induce CCL20 expression is via interaction with the C/EBP 
transcription factors, or via interaction with AP-1 proteins in certain circumstances (Chapter 
4.1.5). Furthermore, the NFκB binding site is not necessary for the dex-induced activation of 
the CCL20 promoter, but rather confers a repressive effect. TNFα and PMA are able to induce 
both the endogenous and pGL2-MIP-3α CCL20 promoter, with LPS approaching statistical 
significance (Fig 3.7). TNFα, PMA and LPS cannot induce the NFκB mutated promoter (Fig 3.8). 
Therefore, the transcription factors used to induce the endogenous and reporter promoter are 
most likely the same; via NFκB. The mechanism for potentiating the dex response is also most 
likely similar; both the GR and NFκB/AP-1 are bound to the CCL20 promoter and produce an 
enhanced effect on CCL20 induction. IFNγ can induce expression and potentiate the dex 
response on the endogenous reporter, most likely via the STAT binding site, and potentiate the 
dex response when the GR is also bound to the promoter. On the pGL2-MIP-3α promoter, 
however, where the STAT binding site is not present, IFNγ represses the basal level of 
expression and dex activation of the promoter. This repression function of the CCL20 promoter 
does not require the STAT, or NFκB binding site as seen on the mutated pGL2-MIP-3α/mκB 
reporter construct.  
 
Data in this thesis has shown that dex is able to activate the CCL20 via the GR, but not 
necessarily via the GR binding to a GRE on the putative promoter. While the NFκB binding site 
is important for the induction by pro-inflammatory ligands, dex is still able to induce the 
promoter. Therefore, targeting the dex mediated activation of CCL20 should not necessarily 
be done by modulating the GR/ NFκB interaction, but rather by GR interacting with other 
transcription factors, such as AP-1 and C/EBP. It has also been shown the CCL20 promoter is 
most likely induced, and suppressed by some ligands at the same time, with the overall 
resulting induction a combinatorial effect. This is seen with IFNγ repressing the induction when 






Figure 4.2. Observed effects of endogenous CCL20 mRNA and pGL2-MIP-3α promoter activity.  
The effect of different ligands on the expression and activation of the putative endogenous CCL20 





4.1.7 Physiological relevance of CCL20 regulation 
 
CCL20 is implicated in the progression of many diseases, such as rheumatoid arthritis and 
inflammatory bowel disease, and also in GC insensitivity in asthma patients (J. Kwon et al., 
2002; A. Lee et al., 2014; Zijlstra et al., 2014). Understanding the mechanisms and signalling 
pathways behind the regulation of CCL20 by inflammatory inducers can provide better insights 
on how to prevent such pathological effects of CCL20. Furthermore, the fact the GCs, which 
are classically used to treat inflammation and cytokine production, enhance the expression of 
CCL20 and potentiate the effects of inflammatory inducers in a variety of cell types, warrants 
further investigation into the regulation of CCL20 expression.  
 
An undesirable side-effect of GC use is GC insensitivity, which is thought to be due to an 
increase in Th17 cells in the lungs of asthma patients. Inflammation mediated by Th17 cells has 




Since CCL20 is a chemoattractant for Th17 cells, and GCs can regulate and potentiate the TNFα 
and LPS responses on CCL20 expression, an understanding of the mechanisms of GC regulation 
of CCL20 is important. The designing of GCs which have little or no activity on CCL20, or the 
use of ‘add-on’ therapies to potentiate the desired anti-inflammatory effects of GCs such as 
long-acting β2 adrenoreceptor agonists (LABAs) and phosphodiesterase 4 inhibitors can be 
more effective with the knowledge of the underlying mechanisms. 
 
CCL20 may be implicated in an increase of HIV-1 acquisition at mucosal epithelial barriers such 
as the cervix, or oral epithelial cells (Chapter 1.3.3). This is further exacerbated at inflamed 
epithelial cells, such as during menstruation (Dieu-Nosjean et al., 2000; Evans et al., 2012). 
CCL20 has been shown to be a possible anti‐HIV‐1 molecule, via direct interaction with HIV-1 
(M. Ghosh et al., 2009).  CCL20, however, still causes an increase in Th17 cells and may 
therefore still increase the rate of HIV-1 infection, especially if the HIV-1 titre is high. There is 
a potential for contraceptives such as medroxyprogesterone acetate (MPA), which has been 
reported to have GC-like properties, to increase CCL20 expression. MPA can therefore 
potentiate the CCL20 response due to inflammatory inducers such TNFα, which expressed 
during menstruation (Govender et al., 2014). Therefore, a possible mechanism for MPA or GCs 
to increase HIV-1 acquisition in the female genital tract is via an increase CCL20 production.  
The female genital tract hosts a microbial flora and, even if a female is not menstruating, the 
presence of LPS may potentiate GC’s response on CCL20 induction. Infection with pathological 
microbes has been shown to increase HIV-1 susceptibility (Y. Ogawa et al., 2009). This can be 
exacerbated by the presence of GCs as, via CCL20, these may cause the migration of HIV-1 
target cells to the female genital tract. 
 
Greater insight into the mechanisms of CCL20 regulation may lead to the development of more 
effective treatment strategies for diseases and production of drugs lacking undesirable side 
effects. The observation that different signalling pathways can produce different effects, such 
as IFNγ compared to the other inflammatory inducers on the pGL2-MIP3α-LUC promoter (Fig 
3.7C), highlights that an understanding of mechanisms in CCL20 promoter regulation can 









GCs, acting via the GR, are involved in a multitude of cellular functions and responses, such as 
metabolism, cardiovascular function, homeostasis and immune function. Tightly controlled cell 
signalling crosstalk between multiple signals is required for appropriate cellular responses to 
maintain the health of the system. Although the GR is ubiquitously expressed in cells 
throughout the body, much regarding the receptor is still not understood due to the 
complexity of genetic regulation, and the fact that it can crosstalk and modulate the function 
of other signalling pathways. An example of this is the GR’s role in the inflammatory response. 
GC’s have classically been established as a mediator of anti-inflammatory cellular responses; 
however, recent research has highlighted many pro-inflammatory GC effects (Cruz-Topete et 
al., 2015). The pro-inflammatory chemokine CCL20 has been demonstrated to be induced by 
GC’s, and potentiates the response due to inflammatory inducers, such as TNFα, in the HeLa 
cell line. Furthermore, it was established that co-stimulation with GCs and a variety of pro-
inflammatory inducers can cause a synergistic or at least enhanced expression of CCL20. This 
potentiated response resulted in a greater expression of CCL20 compared to either GCs, or 
pro-inflammatory inducer alone. It was established that the GR is required for this induction, 
as inhibition abolished this effect. To further examine the mechanisms behind this crosstalk 
between GCs and pro-inflammatory ligands, a reporter construct with the putative CCL20 
promoter was expressed in the HeLa cell line.  
 
The most significant findings in this study is that only certain binding elements and interactions 
between these elements were required were required for the crosstalk between dex and pro-
inflammatory ligands to upregulate CCL20 expression. This was determined from the CCL20 
promoter-reporter construct. The results shown herein demonstrate that TNFα, PMA and LPS 
require the NFκB binding site on the CCL20 promoter to induce its expression, while IFNγ 
requires the STAT binding site. The lack of a STAT binding site in the CCL20 minimal promoter 
may have resulted in IFNγ repressing the activity of the CCL20 reporter-promoter. This present 
study demonstrates that the NFκB binding region is important for the activation of the CCL20 




study also shows that the GR activates CCL20 expression, most likely via a binding to a GRE or 
via  interacting with the AP-1 or C/EBP sites on the promoter.  
GCs most likely induce CCL20 expression to maintain a protective state, especially in 
immunocompromised areas, where pro-inflammatory inducers will also be present. Acute 
exposure to GC has been shown to be involved in an enhancement of the immune response, 
especially in peripheral regions (Dhabhar, 2002). Therefore, knowledge of GC mediated and 
potentiation with inflammatory inducers can lead to the development of more effective 
treatment strategies which do not have the negative, pathological effects of increased CCL20 
expression. Due to CCL20 being implicated in various diseases such as GC insensitivity in 
asthma, rheumatoid arthritis and inflammatory bowel disease, understanding the mechanisms 
of CCL20 regulation may provide practical medical insights for a variety of diseases. This is 
important especially for chronic diseases such as AIDS, which increased levels of CCL20 
expression due to GCs and pro-inflammatory inducers, may increase acquisition of HIV-1, due 
to the migration of leukocytes to the epithelial barriers.  
 
CCL20 is a chemoattract and its sole cognate receptor CCR6 is expressed predominantly on 
Th17 cells. There is evidence suggesting strong correlation between Th17 cells and cancer 
patient survival (Punt et al., 2015). That is, high numbers of Th17 cells in squamous cervical 
cancer improves patient survival, whereas similar numbers of Th17 in other cancers may result 
in poor outcome (Punt et al., 2015). In patients with cancer, synthetic GCs can be a part of 
the cancer treatment because of their pro-apoptotic and anti-inflammatory action (Cook et al., 
2016). The results shown in this study suggest GCs can crosstalk with pro-inflammatory 
immune activators in the tumour microenvironment to upregulate CCL20 expression. The 
result shown herein suggest this may be specific for some and not all cancer cells. However, it 
remains unclear what are the direct effects of elevated CCL20 levels on tumour cells.  
 
The results show that the GR and NFκB are required in the co-regulation of CCL20 expression 
by dex and select pro-inflammatory ligands. This suggests inhibiting the GR or NFκB may 
mitigate the effects on disease outcome mediated by high levels of CCL20. In addition, when 
designing drugs to prevent  GC insensitivity on asthma and its effects in induce CCL20 
implicated in the progression of rheumatoid arthritis, inflammatory bowel disease and an 




drugs should either potentiate the anti-inflammatory effects of GCs, such as by including 
LABAs, or reduce the pro-inflammatory effects of GCs. The latter could be achieved by 
preventing the GR from interacting with transcription factors such as AP-1 or C/EBPβ. However, 
if the overall goal is to supress the expression of CCL20 regardless if cells are stimulated with 
dex or pro-inflammatory ligands, the targeting of NFκB would result in a large decrease in the 
overall induction of CCL20 as seen in the mutated reporter result. Due to the NFκB pathway 
being involved in a variety of cellular functions, the molecules which target this pathway must 
be specific for the intended use with few side effects. A potential source for the discovery of 
molecules that target NFκB can be from pathogenic viruses and bacteria which have been 
shown to produce a large variety of molecules that target NFκB (Rahman et al., 2011).  
 
 
4.3 Future Perspectives 
 
An important question for elucidating the mechanism of GR regulation of CCL20, is finding 
which trascription factors are present on the promoter during its induction. A ChIP assay, 
probing for specific proteins such as the GR, NFκB, C/EBPβ, STAT1 and other co-factors involved 
in their binding, would provide mechanistic insights into CCL20 induction by GCs and pro-
inflammatory inducers. ChIP assays were attempted but they proved unsuccessful, most likely 
due to issues with the reagents in the assay used. Therefore, it could not be determined which 
proteins were bound to the CCL20 promoter under specific conditions. Due to the possibility 
of the GR binding on other transcription factors to possibly cause the potentiated response 
seen, a ChIP done, first targeting the GR, then other transcription factors such as NFκB, AP-1 
C/EBPβ and STAT1 can be performed for the CCL20 promoter. 
 
Changes in the protein levels of transcription factors involved should also be examined. 
Although there were no significant changes in GR or p65 due to stimulation of cells with the 
different ligands, there may be changes in other transcription factors such as AP-1 or MAPKs 
involved in the respective signalling pathways. Post-transcriptional changes such as 
phosphorylation of the GR, or IKK should be investigated, as these affect the activity of these 




translational modifications have been shown to be biomarkers for GR activation (Chapter 
1.1.2.3). Therefore, Western blot analysis of GR phosphorylation, specifically at S211 and S226 
under different conditions would provide insight as to changes in GR conformation, and 
activity. 
The involvement of members of various signalling pathways could also be investigated such as 
via the use of inhibitors to kinases. Activated, phospho-p65 levels should also be examined, 
and the activation of IKK and other kinases within the signalling pathways. 
 
The present study showed apparent synergism in CCL20 induction between dex and the pro-
inflammatory inducers, TNFα, LPS and PMA. This was not shown to be true synergism as a 
Chou-Talalay analysis was not performed (Chou, 2010). Therefore, to show this is indeed true 
synergism, the experimental set-up could be structured to statistically and quantifiably show 
synergism between these factors. An understanding of which treatments result in true synergy 
may give insight into which pathways and mechanisms are involved in causing an increase in 
CCL20 expression, which could possibly be involved in disease progression. These pathways 
could then be drug targets to reduce the level of CCL20 induction, and the possible adverse 
side-effects associated with it. 
 
Once it has been determined which transcription factors are directly involved in CCL20 
induction by the GR, other pro-inflammatory genes that the GR induces can be examined for 
similarities or differences in transcription factor recruitment. Furthermore, any differences or 
similarities in co-factor recruitment on the promoter of pro-inflammatory genes on with which 
synergy occurs between GCs and pro-inflammatory inducers should be examined.  
 
The differences in cell-specific responses should also be compared. The experiments previously 
mentioned could, therefore, be explored in the different cell lines. 
 
It would also be important to determine whether the changes in CCL20 mRNA expression result 
in changes in CCL20 protein, and whether this protein is indeed released by the cells, for it is 
still possible to have post translational CCL20 regulation. This could be done in tissue culture 
via enzyme-linked immunosorbent assays (ELISAs), to determine whether the induced mRNA 




physiological models could be used, such as the use of explant tissue. Furthermore, samples 
from blood or biopsies could be tested for CCL20 protein after exposure to GCs and/or pro-
inflammatory ligands. A migration assay could also be performed to examine whether the 












Supplementary Figure 1. Changes in expression of IL6 when stimulated with dex, TNFα, or a combination 
of both.  
End1 cells were seeded into 12-well plates at a density of 5 x 106 cells/well and incubated for 48 hours. 
Cells were treated with 100 nM dex, 20 ng/mL TNFα, or a combination of both, as stated, in serum-free 
DMEM. Thereafter, the cells were washed twice with PBS and harvested for total RNA with TRIzol® and 
500 ng RNA was reverse-transcribed. CCL20 mRNA expression was measured by qRT-PCR and 




(Vehicle) in order to obtain relative fold expression. Graphs represent pooled results of at least three 
independent experiments and are plotted as mean +/- SEM. Statistical analysis was carried out using 
GraphPad Prism™ software, with different letters representing statistical significance by one-way 
ANOVA, with Tukey's Multiple Comparison Test. Statistical significance by a t-test is denoted by *, **, 
*** or **** to indicate P< 0.05, P< 0.001, P<0.0005 or P< 0.0001, respectively. 
 
 
Supplementary Figure 2. The pro-inflammatory ligands and dex can induce the expression of CCL20 mRNA 
expression and can modulate the dex response in A549 cells.  
A549 cells were seeded into 12-well plates at a density of 5 x 105 cells/well and incubated for 48 hours. 
Cells were treated with 100 nM dex, and/or 5 ng/mL PMA (A), 20 ng/mL IFNγ (B), 5 ng/mL LPS (C), or a 
combination of both, as stated, in serum-free DMEM. Thereafter, the cells were washed twice with PBS 
and harvested for total RNA with TRIzol® and 500 ng RNA was reverse-transcribed. CCL20 mRNA 
expression was measured by qRT-PCR and normalised to GAPDH mRNA expression. Relative gene 
expression was normalized to basal activity (Vehicle) in order to obtain relative fold expression. Graphs 
represent pooled results of at least three independent experiments and are plotted as mean +/- SEM. 
Statistical analysis was carried out using GraphPad Prism™ software, with different letters representing 
statistical significance by one-way ANOVA, with Tukey's Multiple Comparison Test. Statistical 







Supplementary Figure 3. The GR is required for the dex response on CCL20 mRNA, as the GR inhibitor 
RU486 abolishes the response and the dex modulation of TNFα, PMA, IFNγ and LPS.  
HeLa cells were seeded into 12-well plates at a density of 5 x 105 cells/well and incubated for 48 hours. 
Cells were treated HeLa cells were seeded into 12-well plates at a density of 5 x 105 cells/well and 
incubated for 48 hours. Cells were treated with 1 nM RU486, 100 nM dex 20 ng/mL and/or TNFα (A), 
and/or 5 ng/mL PMA (B), 20 ng/mL IFNγ (C), 5 ng/mL LPS (D), as stated in the presence or absence of 
100 nM dex, or 100nM dex alone as stated, in serum-free DMEM for 24 hours. Thereafter, the cells 
were washed twice with PBS and harvested for total RNA with TRIzol® and 500 ng RNA was reverse-
transcribed. CCL20 mRNA expression was measured by qRT-PCR and normalised to GAPDH mRNA 
expression. Relative gene expression was normalized to basal activity (Vehicle) in order to obtain 
relative fold expression. Graphs represent pooled results of at least three independent experiments 
and are plotted as mean +/- SEM. Statistical analysis was carried out using GraphPad Prism™ software, 
with Statistical significance by one-way ANOVA, with Tukey's Multiple Comparison Test denoted by #, 
##, ###, or ####  to indicate P< 0.05, P< 0.001, P<0.0005 or P< 0.0001, respectively. Statistical 







Supplementary Figure 4. Mutation of the NFκB binding site on the CCL20 promoter-reporter construct 
causes a reduction of activation by the pro-inflammatory ligands and dex compared to the wild-type 
promoter. 
HeLa cells were seeded into 48-well plates at a density of 5 x 105 cells/well. The following day, the cells 
were transiently transfected with either 250 ng pGL2-MIP3α-LUC or pGL2-MIP3α/κBm-LUC DNA. Cells 
were treated with either 20 ng/mL TNFα (A), 20 ng/mL PMA (B) 5 ng/mL LPS (C), or 20 ng/mL IFNγ (D), 
in the presence or absence of 100 nM dex, as stated, in serum-free DMEM. Total cells were harvested, 
and RLUs measured via a luminometer and normalised to protein content, determined with a Bradford 
assay. Graphs represent pooled results of at least three independent experiments and are plotted as 
mean +/- SEM. Statistical analysis was carried out using GraphPad Prism™ software, with Statistical 
significance by one-way ANOVA, with Tukey's Multiple Comparison Test denoted by *, **, *** or **** 
















Supplementary Figure 5. Standard curves generated to determine the efficiency of the CCL20 and GAPDH 
primer sets.  
Primer efficiencies were used to determine relative transcript levels by the method described by Pfaffl 
et al. 2002. The Ct values were determined using the Rotogene software for CCL20 and GAPDH (A and 
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